chronic fatigue syndrome

Pizzorno: Textbook of Natural Medicine, 2nd ed., Copyright © 1999 Churchill Livingstone, Inc.

Chapter 49 – Chronic fatigue syndrome

________________________________________
Michael T. Murray ND
Joseph E. Pizzorno Jr ND
________________________________________
DIAGNOSTIC SUMMARY
• Mild fever
• Recurrent sore throat
• Painful lymph nodes
• Muscle weakness
• Muscle pain
• Prolonged fatigue after exercise
• Recurrent headache
• Migratory joint pain
• Depression
• Sleep disturbance (hypersomnia or insomnia).
INTRODUCTION
The chronic fatigue syndrome (CFS) is a newly established syndrome that describes varying combinations of symptoms including recurrent fatigue, sore throats, low-grade fever, lymph node swelling, headache, muscle and joint pain, intestinal discomfort, emotional distress and/or depression, and loss of concentration.
Although newly defined and currently popular, CFS is not a new disease at all. References to a similar condition in the medical literature go back as far as the 1860s. In the past, chronic fatigue syndrome has been known by a variety of names including, among many others:
• chronic mononucleosis-like syndrome or chronic EBV syndrome
• Yuppie flu
• postviral fatigue syndrome
• post-infectious neuromyasthenia
• chronic fatigue and immune dysfunction syndrome (CFIDS)
• Iceland disease
• Royal Free Hospital disease.
In addition, symptoms of chronic fatigue syndrome mirror symptoms of neurasthenia, a condition first described in 1869.
________________________________________
426
Definition
In response to the growing interest, chronic fatigue syndrome was formally defined in 1988 by a consensus panel convened by the Centers for Disease Control (CDC) in an attempt to establish a guide for evaluating patients with chronic fatigue of unknown cause by clinical physicians and researchers.[1]
A formal (and controversial) set of diagnostic criteria were established by the CDC (see Table 49.1 ). These criteria are controversial for many reasons including the fact that psychological symptoms are both a minor criterion and potential grounds for exclusion. One of the major complaints from physicians about the CDC definition is that it appears better suited for research than for clinical purposes. A major problem with the CDC criteria is that they ignore many of the common symptoms reported by patients with CFS (see Table 49.2 ).
The British and Australian criteria for the diagnosis of CFS are less strict than the CDC definition.[2] In particular, the minor diagnostic criteria are not required and the major diagnostic criteria are not as strict. For example, in the Australian definition the major criterion is simply fatigue at a level which causes disruption of daily activities in the absence of other medical conditions associated with fatigue.
Using the CDC criteria, the prevalence of CFS in individuals suffering from chronic fatigue in the United States is thought to be about 11.5%, using British criteria
TABLE 49-1 — CDC diagnostic criteria for chronic fatigue syndrome
Major criteria
• New onset of fatigue causing 50% reduction in activity for at least 6 months
• Exclusion of other illnesses that can cause fatigue
Minor criteria
• Presence of eight of the 11 symptoms listed below, or six of the 11 symptoms and two of the three signs
Symptoms
1. Mild fever
2. Recurrent sore throat
3. Painful lymph nodes
4. Muscle weakness
5. Muscle pain
6. Prolonged fatigue after exercise
7. Recurrent headache
8. Migratory joint pain
9. Neurological or psychological complaints
—sensitivity to bright light
—forgetfulness
—confusion
—inability to concentrate
—excessive irritability
—depression
10. Sleep disturbance (hypersomnia or insomnia)
11. Sudden onset of symptom complex
Signs
1. Low-grade fever
2. Non-exudative pharyngitis
3. Palpable or tender lymph nodes

TABLE 49-2 — Frequency of symptoms in CFS
Symptom/sign Frequency (%)
Fatigue 100
Low-grade fever 60–95
Muscle pain 20–95
Sleep disorder 15–90
Impaired mental function 50–85
Depression 70–85
Headache 35–85
Allergies 55–80
Sore throat 50–75
Anxiety 50–70
Muscle weakness 40–70
Post-exercise fatigue 50–60
Premenstrual syndrome (women) 50–60
Stiffness 50–60
Visual blurring 50–60
Nausea 50–60
Dizziness 30–50
Joint pain 40–50
Dry eyes and mouth 30–40
Diarrhea 30–40
Cough 30–40
Decreased appetite 30–40
Night sweats 30–40
Painful lymph nodes 30–40

it is about 15%, and using the Australian criteria it is about 38%. [2]
ETIOLOGY
Epstein–Barr virus
Many research studies have focused on identifying an infectious agent as the cause of CFS. The Epstein–Barr virus (EBV) emerged as the leading, yet controversial, candidate.[3] [4] [5] [6] [7] EBV is a member of the herpes group of viruses, which includes herpes simplex types 1 and 2, varicella zoster virus, cytomegalovirus, and pseudorabies virus. A common aspect of these viruses is their ability to establish a life-long latent infection after the initial infection. This latent infection is kept in check by a normal immune system. When the immune system is compromised in any way, these viruses can become active as viral replication and spread is increased. This is commonly observed with herpes virus infections, especially in immunocompromised individuals such as those with AIDS, cancer, or drug-induced immunosuppression.
Infection with EBV is inevitable among humans. By the end of early adulthood, almost all individuals demonstrate detectable antibodies in their blood to the Epstein–Barr virus, indicating past infection. When the primary infection occurs in childhood, there are usually no symptoms, but when it occurs in adolescence or early adulthood, the clinical manifestations of infectious mononucleosis develop in approximately 50% of the cases.
________________________________________
427
Although reports of a prolonged or recurrent mononucleosis-like syndrome began appearing in the 1940s and 1950s, it wasn’t until the 1980s that evidence had implicated EBV in this broad clinical spectrum of chronic fatigue and associated symptoms. Numerous studies have now demonstrated persistently elevated titers (levels) of serum antibodies against the Epstein–Barr virus (specifically, anti-EBV capsid antibody titers > 1:80) in a number of patients presenting with the symptom pattern of this syndrome.
A careful study of 134 patients who had undergone EBV antibody testing because of suspected chronic mononucleosis-like syndrome found mixed results about the importance of EBV infection.[8] Fifteen patients identified as having severe, persistent fatigue of unknown origin were compared with the remaining 119 with less severe illness and with 30 age- and race-matched controls. The more seriously ill patients generally had higher levels of EBV antibodies than did the comparison groups, and, interestingly, they also demonstrated higher antibody titers to cytomegalovirus, herpes simplex viruses types 1 and 2, and measles. This led the researchers to conclude that “some patients with these illnesses (syndromes of chronic fatigue) may have an abnormality of infectious and/or immunologic origin”, and that there remain “questions concerning the relationship between CFS and EBV”.
Current knowledge about EBV infection can be summarized as follows:
• EBV and the herpes group of viruses produce latent life-long infections.
• The host’s immune system (T-lymphocytes, interferon, and other lymphokines) normally holds the latent infection in check.
• Any compromise in the immune system can lead to the reactivation of the virus and recurrent infection.
• The infection itself can compromise and/or disrupt immunity, thereby leading to other diseases.
• Elevated EBV antibody levels are observed in a significant number of diseases characterized by immunological dysfunction.
• Elevated antibody titers to the herpes group viruses, measles, and other viruses have also been observed in patients with chronic fatigue syndrome.
EBV antibody testing (and antibody testing for other herpes group viruses and measles) may be useful as a measure of immune function and overall host resistance, but should not be relied upon for diagnosis of CFS.
Other infectious agents
In addition to EBV, a number of other viruses have been investigated as possible causes of EBV. This search

TABLE 49-3 — Organisms proposed as causative agents in CFS
• Epstein–Barr virus
• Human herpes virus-6
• Inoue–Melnich virus
• Brucella
• Borrelia burgdorferi
• Giardia lamblia
• Cytomegalovirus
• Enterovirus
• Retrovirus

for a viral agent is consistent with the mainstream medical approach to focus on the infectious organism rather than on reducing susceptibility and supporting the individual’s immune system to deal with the organism effectively.[3] [4] [5] Table 49.3 lists the organisms currently proposed as causative agents in CFS.
Immune system abnormalities
There is little argument that a disturbed immune system plays a central role in CFS. A variety of immune system abnormalities have been reported in CFS patients (see Table 49.4 ). While no specific immunological dysfunction pattern has been recognized, the most consistent abnormality is a decreased number or activity of natural killer (NK) cells.[3] [4] [9] [10] NK cells received their name because of their ability to destroy cells that have become cancerous or infected with viruses. In fact, for a time, CFS was also referred to as low natural killer cell syndrome (LNKS).
Other consistent findings include a reduced ability of lymphocytes, key in the battle against viruses, to respond to stimuli.[10] One of the reasons for this lack of response may be a reduced activity or decreased production of interferon. While both low and high levels of interferon have been reported in CFS, levels are depressed in most cases. When interferon levels are low, reactivation of latent viral infection is likely. Conversely, when interferon (as well as other chemical mediators like interleukin-1) levels are high, many of the symptoms may be related to the physiological effects of interferon. When interferon is used as a therapy in cancer and viral hepatitis, the side-effects produced are quite similar to the symptoms of CFS.
TABLE 49-4 — Immunologic abnormalities reported for CFS
• Elevated levels of antibodies to viral proteins
• Decreased natural killer cell activity
• Low or elevated antibody levels
• Increased or decreased levels of circulating immune complexes
• Increased cytokine (e.g. interleukin-2) levels
• Increased or decreased interferon levels
• Altered helper/suppressor T-cell ratio

________________________________________
428
Chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities
Fibromyalgia (FM) and multiple chemical sensitivities (MCS), like CFS, are recently recognized disorders with a substantial overlap of symptomatology.[3] [4] [11] [12] The only difference in diagnostic criteria for fibromyalgia and CFS is the requirement of musculoskeletal pain in fibromyalgia and fatigue in CFS. The likelihood of being diagnosed as having fibromyalgia or CFS is dependent upon the type of physician consulted. Specifically, if a rheumatologist or orthopedic specialist is consulted, the patient is much more likely to be diagnosed with fibromyalgia ( Table 49.5 presents the diagnostic criteria for fibromyalgia).
One group of researchers carefully compared the symptomatology of 90 patients who had been diagnosed as having CFS, MCS or FM (30 in each category).[12] Utilizing the same questionnaire for all 90 patients, 70% of the patients diagnosed with FM and 30% with MCS met the Centers for Disease Control criteria for CFS. Particularly significant was the observation that 80% of both the FM and MCS patients met the CFS criteria of fatigue lasting more than 6 months with a 50% reduction in activity. More than 50% of the CFS and FM patients reported adverse reactions of various chemicals.
Other causes of chronic fatigue
Chronic fatigue can be caused by a variety of physical and psychological factors. Table 49.6 lists the major causes of chronic fatigue in an order of importance that is representative of how common the cause is among sufferers of chronic fatigue in the general population. The list is based on the findings of several large studies as well as the authors’ clinical experience (chronic fatigue syndrome is listed under a broader category of impaired immune function).
TABLE 49-5 — Diagnostic criteria for fibromyalgia. Diagnosis requires fulfillment of all three major criteria and four or more minor criteria
Major criteria
• Generalized aches or stiffness of at least three anatomic sites for at least 3 months
• Six or more typical, reproducible tender points
• Exclusion of other disorders which can cause similar symptoms
Minor criteria
• Generalized fatigue
• Chronic headache
• Sleep disturbance
• Neurological and psychological complaints
• Joint swelling
• Numbing or tingling sensations
• Irritable bowel syndrome
• Variation of symptoms in relation to activity, stress, and weather changes

TABLE 49-6 — Causes of chronic fatigue
• Pre-existing physical condition
—diabetes
—heart disease
—lung disease
—rheumatoid arthritis
—chronic inflammation
—chronic pain
—cancer
—liver disease
—multiple sclerosis
• Prescription drugs
—antihypertensives
—anti-inflammatory agents
—birth control pills
—antihistamines
—corticosteroids
—tranquilizers and sedatives
• Depression
• Stress/low adrenal function
• Impaired liver function and/or environmental illness
• Impaired immune function
—chronic fatigue syndrome
—chronic Candida infection
—other chronic infections
• Food allergies
• Hypothyroidism
• Hypoglycemia
• Anemia and nutritional deficiencies
• Sleep disturbances
• Cause unknown

DIAGNOSIS
A great number of factors must be considered when evaluating a patient with chronic fatigue. A detailed medical history and review of body systems goes a long way to identifying important factors. The goal is to identify as many factors as possible which may be contributing to the patient’s feeling of fatigue. For example, if a patient has heart disease, diabetes, or some other health condition, and the condition or the drug they are taking is clearly responsible for their fatigue, the treatment of their fatigue becomes secondary to the treatment of their underlying health condition.
In many cases of chronic fatigue, further evaluation is needed. The next steps can include a complete physical examination and laboratory studies. In the physical examination, look for any possible clues which may indicate the cause for the chronic fatigue. For example, swollen lymph nodes may indicate a chronic infection; and the presence of a diagonal crease on both ear lobes usually indicates impaired blood flow to the brain, a significant cause of fatigue in the elderly.
Avoid ordering expensive laboratory tests unless they are absolutely necessary. A complete blood count (CBC) and a chemistry panel (including serum ferritin in menstruating women) are useful as screening tools for other diseases. Avoid ordering laboratory tests to confirm a diagnosis that is not going to affect treatment. For example, if it is quite obvious that the patient has
________________________________________
429
impaired immunity, it does not make much sense to perform elaborate and expensive blood tests on immune function because the results of these tests are not likely to influence the method of treatment.
Of particular value are assessment of liver detoxification function, bowel dysbiosis and gastrointestinal permeability (see Chs 9 , 16 and 21 ).
THERAPEUTIC CONSIDERATIONS
Since chronic fatigue and the CFS are generally multifactorial conditions, the therapeutic approach typically involves multiple therapies which address different facets of the clinical picture.
A person’s energy level, as well as their emotional state, is determined by an interplay between two primary factors – internal focus and physiology. Many people with chronic fatigue focus on how tired they are. They repeatedly reaffirm their fatigue to themselves and to anyone who will listen. Their physiology includes not only the chemicals and hormones floating around in the body, but also the way they hold their body (usually slouched) and the way they breathe (shallow). In most patients with chronic fatigue, both the mind and the body need to be addressed. The most effective treatment is a comprehensive program that is designed to help the use of their mind, attitude, and physiology to fuel higher energy levels.
Underlying health problems
Depression
The first factor to address is any underlying depression. Depression is one of the major causes of chronic fatigue and it is one of the common features of CFS. In the absence of a pre-existing physical condition, depression is generally regarded as the most common cause of chronic fatigue. However, it is often difficult to determine whether the depression preceded the fatigue or vice versa. Depression is fully discussed in Chapter 126 .
Stress
Stress is another factor to consider in the patient with chronic fatigue or CFS. Stress can be the underlying factor in the patient with depression, low immune function, or other cause of chronic fatigue (see Ch. 60 for guidelines for assessing the role of stress in chronic fatigue and CFS).
One of the tools we recommend to rate stress levels is the “Social Readjustment Rating Scale” developed by Holmes & Rahe.[13] The scale was originally designed to predict the likelihood of a person getting a serious disease due to stress. Various life-change events are numerically rated according to their potential for causing disease. Even events commonly viewed as positive, such as an outstanding personal achievement, carry with them stress.
Impaired liver function and/or environmental illness
Exposure to food additives, solvents (cleaning materials, formaldehyde, toluene, benzene, etc.), pesticides, herbicides, heavy metals (lead, mercury, cadmium, arsenic, nickel, and aluminum), and other toxins can greatly stress liver and detoxification processes. This exposure can lead to a condition labeled by many naturopathic and nutrition-oriented physicians as the “congested liver” or “sluggish liver” or the more recently coined “impaired hepatic detoxification”. These terms signify a reduced ability of the liver to detoxify. The congested or sluggish liver is characterized by a diminished bile flow, a condition known in medical terms as cholestasis, while impaired hepatic detoxification refers to decreased phase I and/or phase II enzyme activity. Phase I detoxification rates in excess of phase II activity will also cause toxicity problems due to excessive accumulation of activated intermediates (see Ch. 16 ). In addition to exposure to toxic chemicals, impairment of bile flow within the liver can be caused by a variety of other agents and conditions, as listed in Table 49.7 .
Although many of the conditions listed in the table are typically associated with alterations in laboratory tests of liver function (serum bilirubin, AST, ALT, LDH, GGTP, etc.), relying on these tests alone to evaluate liver function may not be adequate, as these tests are elevated only when the liver has been significantly damaged and many of these conditions in the initial or “subclinical” stages may have normal laboratory values.
TABLE 49-7 — Causes of cholestasis
• Dietary factors
—saturated fat
—refined sugar
—low fiber intake
• Obesity
• Diabetes
• Presence of gallstones
• Alcohol
• Endotoxins and other gut-derived bacterial toxins
• Hereditary disorders such as Gilbert’s syndrome
• Pregnancy
• Natural and synthetic steroid hormones
—anabolic steroids
—estrogens
—oral contraceptives
• Certain chemicals or drugs
—cleaning solvents
—pesticides
—antibiotics
—diuretics
—non-steroidal anti-inflammatory drugs
—thyroid hormone
—viral hepatitis

________________________________________
430
Although there are more sensitive tests to determine the functional activity of the liver, such as the serum bile acid assay and various clearance tests (see Ch. 16 ), clinical judgment based on medical history remains the major diagnostic tool for the “sluggish liver” or impaired hepatic detoxification enzymes, the presence of chronic fatigue being the hallmark symptom.
People with a sluggish liver may also complain of, among other things:
• depression
• general malaise
• headaches
• digestive disturbances
• allergies and chemical sensitivities
• premenstrual syndrome
• constipation.
Not surprisingly, these are the same types of symptoms that people exposed to toxic chemicals often complain of. Many toxic chemicals (especially solvents) and heavy metals (see Ch. 18 ) have an affinity to nervous tissue, giving rise to a variety of psychological and neurological symptoms, such as:[14] [15]
• depression
• headaches
• mental confusion
• mental illness
• tingling in extremities
• abnormal nerve reflexes
• other signs of impaired nervous system function.
A hair mineral analysis is a good screening test for heavy metal toxicity. If the hair mineral analysis is inconclusive, a more sensitive indicator is the 8 hour lead mobilization test. This test employs the chelating agent EDTA (edetate calcium disodium) and measures the level of lead excreted in the urine for a period of 8 hours after the injection of EDTA.
An interesting multiclinic research study of chronically ill patients, many of whom were diagnosed as suffering from CFIDS, evaluated the efficacy of a comprehensive detoxification program. Patients were placed on a hypoallergenic diet and provided a dietary food supplement rich in nutrients that facilitate liver detoxification. The patients reported a 52% reduction in symptoms after 10 weeks and symptom improvement was mirrored by normalization of hepatic phase I and phase II detoxification.[16]
Excessive gastrointestinal permeability
Excessive gastrointestinal permeability, as measured by the lactulose/mannitol absorption test (see Ch. 21 ), is a common finding in CFS.[17] A treatment program utilizing food allergy control, nutrients to stimulate gastrointestinal regeneration and to support hepatic phase I and II detoxification, and an oligoantigenic rice protein food replacement formula was provided to 22 patients who fulfilled the classic CDC/NIH criteria for CFS. The patients’ average duration of CFS was 4.6 years. The treatment resulted in symptom reduction in 81.2% of the patients, with clinical improvement being paralleled by normalization of gastrointestinal permeability and hepatic detoxification function.[18]
Impaired immune function and/or chronic infection
When the immune system is impaired, infections can linger and fatigue persist. There is a good reason for fatigue during an infection – fatigue is the body’s response mechanism to infection because the immune system works best when the body is at rest.
In order to determine the role that the immune system is playing in patients with chronic fatigue, the series of questions listed in Table 49.8 can be utilized during the patient interview to indicate an impaired immune system. Chapter 20 describes in substantial detail the laboratory methodologies for assessing immune function.
Chronic Candida infection
One of the most common findings in individuals with impaired immune function is gastrointestinal overgrowth of Candida albicans. Candidal overgrowth is now becoming recognized as a complex medical syndrome also known as “the yeast syndrome” and “chronic candidiasis”. This overgrowth is believed to cause a wide variety of symptoms in virtually every system of the body, with the gastrointestinal, genitourinary, endocrine, nervous, and immune systems being the most susceptible. Table 49.9 lists the typical chronic candidiasis patient profile (see Ch. 48 for a comprehensive discussion).
The diagnosis of chronic candidiasis is often quite difficult as there is no single specific diagnostic test. Stool cultures and elevated antibody levels to Candida are useful diagnostic aids, but they should not be relied upon for diagnosis. The best method for diagnosing chronic candidiasis in most cases is a detailed medical history and patient questionnaire (see Appendix 2 ). Table 49.10 lists the factors that typically predispose a patient to candidal overgrowth.
TABLE 49-8 — Questionnaire for recognition of impaired immune function
• Do you get more than two colds per year?
• When you catch a cold, does it take more than 5–7 days to get rid of the symptoms?
• Have you ever had infectious mononucleosis?
• Do you have herpes?
• Do you suffer from chronic infections of any kind?

________________________________________
431

TABLE 49-9 — Typical chronic candidiasis patient profile
• Sex: female
• Age: 15–50 years
General symptoms
• Chronic fatigue
• Loss of energy
• General malaise
• Decreased libido
Gastrointestinal symptoms
• Thrush
• Bloating, gas
• Intestinal cramps
• Rectal itching
• Altered bowel function
Genitourinary system complaints
• Vaginal yeast infection
• Frequent bladder infections
Endocrine system complaints
• Primarily menstrual complaints
Nervous system complaints
• Depression
• Irritability
• Inability to concentrate
Immune system complaints
• Allergies
• Chemical sensitivities
• Low immune function
Past history
• Chronic vaginal yeast infections
• Chronic antibiotic use for infections or acne
• Oral birth control usage
• Oral steroid hormone usage
Associated conditions
• Premenstrual syndrome
• Sensitivity to foods, chemicals, and other allergens
• Endocrine disturbances
• Psoriasis
• Irritable bowel syndrome
Other
• Craving for foods rich in carbohydrates or yeast

TABLE 49-10 — Factors predisposing to Candida overgrowth
• Impaired immune function
• Anti-ulcer drugs
• Broad-spectrum antibiotics
• Cellular immunodeficiency
• Corticosteroids
• Diabetes mellitus
• Excessive sugar in the diet
• Intravascular catheters
• Intravenous drug use
• Lack of digestive secretions
• Oral contraceptive agents

Food allergies
As far back as 1930, chronic fatigue was recognized as a key feature of food allergies.[19] Originally, Rowe & Rowe [19] used the term “allergic toxemia” to describe a syndrome that included the symptoms of fatigue, muscle and joint aches, drowsiness, difficulty in concentration, nervousness, and depression. Around the 1950s, this syndrome began to be referred to as the “allergic tension-fatigue syndrome”.[20] With the popularity of CFS, many physicians and others are forgetting that food allergies can lead to chronic fatigue. Furthermore, between 55 and 85% of individuals with CFS have allergies. For more information on food allergies, see Chapter 15 .
Hypothyroidism
Hypothyroidism is a common cause of chronic fatigue. However, the condition is often overlooked. The reason for this may be the reliance on standard blood measurements of thyroid hormone levels as the method of diagnosis.[21] [22] [23] Undiagnosed hypothyroidism is a serious concern as failure to treat such a critical and underlying problem will reduce the effectiveness of every other measure designed to increase energy levels. For more information, see Chapter 162 .
Hypoglycemia
The association between hypoglycemia and fatigue is well known. What is not as well known is the role that hypoglycemia plays in contributing to depression. Numerous studies have shown that depressed individuals suffer from hypoglycemia.[24] [25] [26] [27] Since depression is the most common cause of chronic fatigue, hypoglycemia must always be ruled out (see Ch. 161 ).
Hypoadrenalism
Adrenal exhaustion was first proposed as a cause of chronic fatigue over 50 years ago by Tintera.[28] A small, but growing, body of evidence now supports the role of a disruption of the hypothalamic–pituitary–adrenal axis (HPA) in CFS.[29]
One of the major symptoms of glucocorticoid deficiency is debilitating fatigue. Glucocorticoid insufficiency is also characterized by a stressing event followed by feverishness, arthralgias, myalgias, adenopathy, post-exertional fatigue, exacerbation of allergic responses and disturbances of mood and sleep, i.e. the typical presentation of CFS. These symptoms are seen in partial or subclinical adrenal insufficiency, which may only be detected by the ACTH stimulation test or other endocrine testing. Glucocorticoids have a very profound endogenous immunosuppressive effect. In subclinical adrenal insufficiency, this may allow for the symptoms of chronic fatigue, including exacerbation of allergic responses, enhanced antibody titers to a variety of viral antigens, and elevations in cytokine levels. A group of CFS researchers believe that these patients form a heterogenous group with a variety of infectious and non-infectious antecedents.[29] They feel that chronic fatigue syndrome
________________________________________
432
does not represent a discrete disease with a singular cause, but rather a clinical condition. Chronic fatigue syndrome is analogous to a number of complex medical conditions such as hypertension in which a variety of direct and indirect factors lead to the development of the clinical syndrome.
The researchers hypothesize that in chronic fatigue syndrome, specific pathophysiological antecedents, such as acute infection, stress, and pre-existing or concurrent psychiatric illness, may ultimately converge in a final common biological pathway resulting in the clinical syndrome of chronic fatigue syndrome. They believe that their data and others suggest that a reduction in adrenal cortical secretion is an important pathophysiological component in the development of many of the biological and behavioral features of the syndrome.
For example, in one of their studies, 30 patients with classically defined chronic fatigue syndrome were compared with 72 normal volunteers and patients.[30] The CFS patients were found to have significantly reduced evening cortisol levels and low 24 hour urinary free cortisol excretion. The CFS patients also had elevated basal ACTH concentrations and increased adrenal cortical sensitivity to ACTH, but a reduced maximal response, and showed attenuated net integrated ACTH response to corticotrophin-releasing hormone. These results are most compatible with a mild, central, adrenal insufficiency, secondary to either a deficiency of CRH or some other central stimulus to the pituitary–adrenal axis. The authors feel that the hyperresponsiveness of the adrenal cortex to ACTH in patients with chronic fatigue syndrome may reflect a secondary adrenal insufficiency in which adrenal ACTH receptors have become hypersensitive due to inadequate exposure to ACTH. The reduction in response to large doses of ACTH might suggest overall adrenal atrophy. The evidence suggests that the mild hypocortisolism in these patients reflects a defect at or above the level of the hypothalamus, resulting in deficiency in the release of CRH and/or other secretagogs that serve to activate the pituitary–adrenal axis.
Mind and attitude
The mind and attitude play a critical role in determining the status of the immune system and energy levels. Many patients with chronic fatigue (including CFS) are either depressed or just seem to have lost a sense of real enthusiasm for life. Of course, it is not easy to have a lot of enthusiasm when you do not have much energy. But the two usually go hand in hand.
The first step is to convey to CFS patients that they can get better. Many patients with CFS are told it is “something they will have to live with” and “there is no cure”. Achieving or maintaining a positive mental attitude is critical to good health and high energy levels, especially in patients with CFS. In order to achieve a positive mind, a person needs to exercise or condition the attitude, similar to the way in which one would condition the body. In order to help patients, prescribe mental exercises such as visualizations, goal setting, affirmations, and empowering questions as detailed in Chapter 126 .
Diet
Energy level appears to be directly related to the quality of the foods routinely ingested. Have patients adhere to the dietary guidelines given in Chapter 44 . It is especially important to eliminate or restrict caffeine and refined sugar.
Although acute caffeine consumption provides stimulation, regular caffeine intake may actually lead to chronic fatigue. While mice fed one dose of caffeine demonstrated significant increases in their swimming capacity, when the dose of caffeine was given for 6 weeks, a significant decrease in swimming capacity was observed.[31]
It is also interesting to note that several studies have found caffeine intake to be extremely high in individuals with psychiatric disorders. Another interesting finding is that the degree of fatigue experienced is often related to the quantity of caffeine ingested. In one survey of hospitalized psychiatric patients, 61% of those ingesting at least 750 mg/day (at least five cups of coffee) complained of fatigue, compared with 54% of those ingesting 250–749 mg/day, and only 24% of those ingesting less than 250 mg/day.[32]
Be aware that in patients who routinely drink coffee, abrupt cessation of coffee drinking will probably result in symptoms of caffeine withdrawal, including fatigue, headache, and an intense desire for coffee.[33] [34] Fortunately, this withdrawal period does not last more than a few days.
Nutritional supplements
Nutritional supplementation is essential in the treatment of chronic fatigue. A deficiency of virtually any nutrient can produce the symptoms of fatigue as well as render the body more susceptible to infection. Individuals with chronic fatigue require, at the bare minimum, a high potency multiple vitamin–mineral formula, along with extra vitamin C (3,000 mg/day in divided doses) and magnesium (500–1,200 mg/day in divided doses).
Magnesium
An underlying magnesium deficiency, even if subclinical, can result in chronic fatigue and symptoms similar to CFS. In addition, low red blood cell magnesium levels, a more accurate measure of magnesium status than
________________________________________
433
routine blood analysis, have been found in many patients with chronic fatigue and CFS. Several studies have shown good results with magnesium supplementation.
For example, in one double-blind, placebo-controlled trial, 32 CFS patients received an intramuscular injection of either magnesium sulfate (1 g in 2 ml injectable water) or a placebo (2 ml injectable water) for 6 weeks. At the end of the study, 12 of the 15 patients receiving magnesium reported, based on strict criteria, significantly improved energy levels, better emotional state, and less pain. In contrast, only three of the 17 placebo patients reported that they felt better and only one reported improved energy levels.[35]
This study seems to confirm some impressive results obtained in clinical trials during the 1960s on patients suffering from chronic fatigue.[36] [37] [38] [39] These studies utilized oral magnesium and potassium aspartate (1 g each) rather than injectable magnesium. Between 75 and 91% of the nearly 3,000 patients studied experienced relief of fatigue during treatment with the magnesium and potassium aspartate. In contrast, the number of patients responding to a placebo was between 9 and 26%. The beneficial effect was usually noted after only 4–5 days, but sometimes 10 days were required. Patients usually continued treatment for 4–6 weeks; afterwards fatigue frequently did not return.
Injectable magnesium is not necessary to restore magnesium status.[40] Absorption studies indicate that magnesium is easily absorbed orally when it is bound to aspartate or citrate. In addition, both of these compounds may also help fight off fatigue. Aspartate feeds into the Krebs cycle, the final common pathway for the conversion of glucose, fatty acids, and amino acids to chemical energy (ATP), while citrate is itself a component of the Krebs cycle. Krebs cycle components including aspartate, citrate, fumarate, malate, and succinate usually provide a better mineral chelate, as evidence suggests that minerals chelated to the Krebs cycle intermediates are better absorbed, utilized, and tolerated compared with inorganic or relatively insoluble mineral salts, including magnesium chloride, oxide, or carbonate.[40] [41]
Other therapies
Breathing, posture, and bodywork
Proper care of the body is critical to high energy levels. Breathing with the diaphragm, good posture, and bodywork (massage, spinal manipulation, etc.) are all important in helping to relieve the stress that is a common contributor to fatigue.
Exercise
Exercise alone has been demonstrated to have a tremendous impact on improving mood and the ability to handle stressful life situations.[42] Regular exercise has also been shown to lead to improved immune status. For CFS patients, regular exercise has been shown to lead to a significant increase (up to 100%) in natural killer cell activity.[43] [44] Although more strenuous exercise is required to benefit the cardiovascular system, light to moderate exercise may be best for the immune system. One study found that immune function was significantly increased by the practice of t’ai chi exercises.[45] T’ai chi is a martial art technique which features the movement from one posture to the next in a flowing motion that resembles dance. The research thus far suggests that light to moderate exercise stimulates the immune system, while intense exercise (e.g. training for the Olympics) can have the opposite effect.[46]
Botanical medicine
Eleutherococcus senticosus
In addition to supporting adrenal function and acting as a non-specific adaptogen, Siberian ginseng has been shown to exert a number of beneficial effects on immune function that may be useful in the treatment of CFS. In one double-blind study, 36 healthy subjects received either 10 ml of a fluid extract of Eleutherococcus senticosus or placebo daily for 4 weeks.[47] The group receiving the Siberian ginseng demonstrated significant improvements in a variety of immune system parameters. Most notable were a significant increase in T-helper cells and an increase in natural killer cell activity – both of which are of value in the treatment of CFS.
Glycyrrhiza glabra
Considering the possible roles of viral infection and hypoadrenalism in CFS, licorice root with its antiviral and glucocorticoid potentiating properties (see Ch. 90 for documentation of these properties) would seem to be an ideal botanical for this condition.[48] Unfortunately, this has not been rigorously evaluated, although an excellent response in a single patient has been reported.[49] The whole root must be used as DGL has had the glucocorticoid potentiating glycyrrhizic and glycyrrhetinic acids removed.
THERAPEUTIC APPROACH
Successful treatment of CFS requires a comprehensive diagnostic and therapeutic approach. Especially important is identifying underlying factors which may be impacting energy levels or the immune system. The strong correlation between chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities suggests that all may respond to hepatic detoxification, food allergy control, and a gut restoration diet.[16] [17] [18] [50] Special
________________________________________
434
attention should be paid to the advice on immune support in Chapter 53 .
Diet
Identify and control food allergies. Increase the consumption of water while eliminating consumption of caffeine-containing drinks and alcohol. Strongly suggest a diet of whole, organically grown foods. Control hypoglycemia through the elimination of sugar and other refined foods and the regular consumption of small meals and snacks. To speed the detoxification process, consider prescribing a course lasting for several weeks of a medical food replacement such as one of the UltraClear products.
Lifestyle
Teach the patient diaphragmatic breathing and a proper posture. Prescribe a regular exercise program; low intensity activities may produce greatest benefits.
Supplementation
• High potency multiple vitamin and mineral formula according to guidelines given in Chapter 44
• Vitamin C: 500–1,000 mg three times/day
• Vitamin E: 200–400 IU/day
• Thymus extract: 750 mg of the crude polypeptide fraction once or twice daily
• Magnesium bound to citrate or Krebs cycle intermediates: 200–300 mg three times/day
• Pantothenic acid: 250 mg/day.
Botanical medicines
• Eleutherococcus senticosus
—dried root: 2–4 g
—tincture (1:5): 10–20 ml
—fluid extract (1:1): 2.0–4.0 ml
—solid (dry powdered) extract (20:1 or standardized to contain greater than 1% eleutheroside E): 100–200 mg
• Glycyrrhiza glabra
—powdered root: 1–2 g
—fluid extract (1:1): 2–4 ml
—solid (dry powdered) extract (4:1): 250–500 mg
Counseling
Either counsel the patient directly or refer him or her to a professional counselor to establish a regular pattern of mental, emotional, and spiritual affirmations.

 

 

Thymus Protein

Thymus Protein

4) A Protein From A Common Smoldering Virus Linked To Chronic Fatigue Syndrome And Depression
Main Category: Depression
Also Included In: Psychology / Psychiatry;  Infectious Diseases / Bacteria / Viruses
Article Date: 24 Jun 2008 – 5:00 PDT

A study suggests that a “smoldering” central nervous system (CNS) infection may play a role in conditions that plague millions of Americans. Kazuhiro Kondo, MD, PhD, of the Jikei University Medical School in Tokyo identified a novel human herpesvirus-6 (HHV-6) protein present in Chronic Fatigue Syndrome (CFS) patients but not healthy controls that may contribute to psychological symptoms often associated with that and other disorders.

“Causes of many chronic diseases are unknown and chronic viral infection is one of the most suspected candidates,” said Dr. Kondo, who spent 20 years trying to identify the latent protein responsible for chronic CNS disease and mood disorders.

Support for Dr. Kondo’s claim came from Stanford University’s Jose Montoya who announced at the same conference that the antiviral drug Valcyte, shown to be effective against HHV-6, resulted in an improvement in the cognitive functioning of CFS patients, although not a complete resolution of their fatigue. According to Dr. Kondo, drugs like Valcyte combat active replication but can’t completely control low-level smoldering. “To cure the diseases, we have to reduce the latently infected virus or prevent its reactivation,” he explains.

A Debilitating Disorder

Chronic Fatigue Syndrome is a debilitating disorder affecting one to four million Americans and causing 25 billion dollars a year in economic losses. The primary symptoms include post-exertional malaise, fatigue, difficulty concentrating, unrefreshing sleep, muscle and joint pain. High rates of depression co-occur with the disease.

Mostly striking, in working-age adults, the disease is often triggered by a flu-like episode. Efforts to find a single pathogen responsible for the disease have, however, failed and the cause of the disorder is unknown.

Novel Herpesvirus Protein is Associated with Altered Nervous System Cell Activity and Chronic Fatigue Syndrome and Depression

Kondo identified a novel HHV-6 protein associated with latent (non-replicating) HHV-6-infected nervous system and immune cells. Transfecting this new protein, called SITH-1 (Small Intermediate Stage Transcript of HHV-6), into nervous system cells called glial cells, resulted in greatly increased intracellular calcium levels. Increased intracellular calcium levels are believed to play an important role in psychological disorders and can contribute to cell death. Expressing the SITH protein though the use of an adenoviral vector in mouse resulted in manic-like behavior.

A serological study indicated that 71% of CFS patients with psychological symptoms and none of the health controls possessed the antibody against the SITH-1 protein (p < .0001). Further tests indicated that 53% of depression and 76% of bipolar depression patients possessed the antibody.

Traditional Viral Tests May Overlook Important Disease Causing Processes

Researchers have suspected that central nervous system infections could contribute to psychological and central nervous system disorders, and patients with CFS have a much higher than average rate of depression. This virus spreads cell-to-cell instead of releasing viral particles into the bloodstream. This has hampered efforts to demonstrate that the virus plays a role in CNS disease. “This virus persists in the brain and other tissues, but not the blood, which is where investigators have looked,” says Kristin Loomis, Executive Director of the HHV-6 Foundation. “Indeed, standard serum PCR DNA for direct evidence of the virus are useless,” she added. New ultra-sensitive assays are under development, she reports, “but currently the best way to identify patients with smoldering HHV-6 infection is to look for elevated IgG antibody titers.”

Dharam Ablashi, the co-discoverer of the HHV-6 virus, and the HHV-6 Foundation’s Scientific Director warns that the test won’t be available in the near future. “It may take years to get the assay validated and into commercial production, but will be worth the wait. This assay could identify large numbers of patients with CNS dysfunction who could benefit from antiviral treatment. The HHV-6 Foundation is working hard to help scientists like Dr. Kondo develop better assays,” says Ablashi.

The HHV-6 Foundation

The HHV-6 Foundation encourages scientific exchanges and provides grants to researchers seeking to increase our understanding of HHV-6 infection in a wide array of central nervous system disorders.

HHV-6 Foundation

Thymus Protein Treats Chronic Fatigue
People with chronic fatigue and immune dysfunction syndrome (also known as chronic fatigue syndrome or CFIDS) may improve their immune function by taking a specific protein derived from the thymus gland, according to a study in the Journal of Nutritional and Environmental Medicine (2001;11:241–7).
CFIDS is a complex illness that includes a broad spectrum of symptoms, including memory or concentration problems, sore throat, swollen lymph nodes, muscle or joint pain, and headaches or sleep disturbances. The most pronounced symptom is chronic, persistent fatigue. In many cases, the fatigue is debilitating to the point that people become unable to work. The underlying cause is unknown and there is no conventional treatment for CFIDS, other than symptomatic support. The new study on thymus protein offers new hope for those suffering from this often-incapacitating condition.
In the study, 23 people with CFIDS received 12 mcg of thymic protein A per day by mouth for three months. This treatment resulted in a significant improvement in several markers of immune function. Perhaps more importantly, the intensity and frequency of CFIDS symptoms decreased in many of the participants. Positive changes included a reduction in fatigue, better quality of sleep, less anxiety and depression, and fewer panic attacks.
The thymus is an important organ involved in regulating the immune system. In people with CFIDS, several cells of the immune system decrease in number and the ability of these cells to respond quickly to a foreign substance (such as a bacterium) is inhibited. Thymic protein A stimulates the immune system in such a way that these specific immune cells increase in number and become more biologically active making them more efficient and better functioning. It is unknown how these changes in immune function ultimately affect one’s symptoms.
The cause of CFIDS has remained a mystery, although some evidence suggests it may be linked with certain viral infections (Epstein-Barr, cytomegalovirus, and human herpes virus 6 have all been mentioned as possible agents). Other studies suggest that the condition may be related to the organisms that cause walking pneumonia or Lyme disease. However, more research is necessary to determine whether the underlying cause is an infectious agent or an abnormality of metabolism. It is possible that the cause is different in different people. Thymic protein A is commercially available in the United States and may be found in some health food stores.
Darin Ingels, ND, MT (ASCP), received his bachelor’s degree from Purdue University and his Doctorate of Naturopathic Medicine from Bastyr University in Kenmore, WA. Dr. Ingels is the author of The Natural Pharmacist: Lowering Cholesterol (Prima, 1999) and Natural Treatments for High Cholesterol (Prima, 2000). He currently is in private practice at New England Family Health Associates located in Southport, CT, where he specializes in environmental medicine and allergies. Dr. Ingels is a regular contributor to Healthnotes and Healthnotes Newswire.
Copyright © 2002 Healthnotes, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
ProBoost for Chronic Fatigue Syndrome and Immune Dysfunction Syndrome
May 6, 2013 by

Proboost Thymic Protein A is an all natural supplement with similar properties to the immune regulating hormone, “thymulin.”  It has been found effective for fighting infections, the common cold, flu viruses, Lyme Disease and it has been shown to have improve immune activation markers for those suffering from Chronic Fatigue Syndrome (CFS) and Chronic Fatigue Immune Dysfunction Syndrome (CFIDS).
What is Chronic Fatigue Syndrome (CFS and CFIDS)
Chronic Fatigue Syndrome (CFS) is a disorder that causes extreme episodes of fatigue.  CFS is a specific type of fatigue that cannot be attributed to an underlying medical condition and is not relieved by rest. It can last for long periods of time, typically more than six months, and incapacitates one’s ability to carry out ordinary daily tasks.
What are the Causes of CFS and CFIDS
The symptoms of CFS and Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) are often similar to other illnesses. It is speculated by the medical community, that CFS may have its roots in one of three areas, especially among people with a predisposition to develop it once triggered (source Mayo Clinic):
• Viral infections. Some people develop chronic fatigue syndrome after a viral infection.  Researchers suspect that some viruses might trigger the disorder. Suspicious viruses have included Epstein-Barr, human herpesvirus 6, Lyme disease and mouse leukemia viruses but none of them has been definitely linked.
• Immune system dysfunction. The immune systems of people who have chronic fatigue syndrome appears to be impaired. It is unclear if this impairment is enough to actually cause the disorder, or a result of it.
• Hormonal imbalances. People who have CFS also sometimes experience abnormal blood levels of hormones produced in the hypothalamus, pituitary gland or adrenal glands. Again, it is unclear if this imbalance is the cause or the effect of it.
Chronic Fatigue Syndrome Symptoms
The main symptom of CFS is extreme fatigue lasting for more than 6 months and includes at least four of the following symptoms:
• Feeling ill for more extended periods
• Memory issues
• Muscle pain
• Pain in joints
• Headaches
• Sore throat
• Tender lymph nodes
• Sleep problems and not feeling rested after sleep
Unfortunately, there are no tests designed to diagnose CFS.   Since there are other illnesses that produce the same type of symptoms, a doctor can rule out other ailments with testing before diagnosing Chronic Fatigue Symptom.
Not much is known about CFS and CFIDS or what is the cause.  It is most common among women in their 40’s and 50’s, but it can affect anyone. What is exceedingly disturbing about CFS is that there is no cure, and it can last for years. The objective is to try to manage the symptoms by some simple changes, such as focusing on varying a few daily routines, learning some coping techniques and exercising regularly. There is medication for the pain and other problems but food sensitivities and digestive issues should not be ruled out as potential factors.
ProBoost for Chronic Fatigue Syndrome
ProBoost is Thymic Protein A, a clinically proven, naturally occurring, 500-chain protein produced by the thymus gland, that may help with Chronic Fatigue Syndrome (CFS). For some users it has been very effective.  There may be a connection to CFS when it is a result of a virus or an immune insufficiency. Where that is the case, then ProBoost, which builds the number of active immune T-cells, targets those specific causes. It is clinically shown that restoring diminishing Thymic Protein A (TPA) results in improved immune response.
How to Take Thymic Protein A
Chronic Fatigue Syndrome (CFS) symptoms can be managed by regularly taking ProBoost. Not only will it help with CFS, Proboost enhances the body’s natural immune response to other undesirable conditions like, colds, flu, cancer and other viruses.
ProBoost Thymic Protein A is taken three times a day when used for an active condition. It comes in pre-measured packets of TPA powder and is placed under the tongue (never swallowed) where it dissolves in about three minutes.  It is important that Thymic Protein A be delivered sublingually as digestive acids can break down it before it reaches the bloodstream. Chronic Fatigue Syndrome symptoms have been shown to improve after taking ProBoost over a 12 week period. Some individuals experience permanent relief, while others find a maintenance dose of 1-2 packets is needed after the initial phase.
How to Order ProBoost
ProBoost Thymic Protein A can be ordered in boxes of 30 packets and can be shipped in any quantity. It is also available for monthly auto-shipped for people using for chronic or prolonged conditions. As always, shipping is fast and free from ProBoost D

Altra teoria sull’origine microbica
Una carenza protratta di glutatione altera la produzione di ossidi di azoto (NO) e radicali di ossigeno gassosi negli immunociti ed in altre cellule dell’organismo. In queste condizioni, le cellule T-4 helper sono presenti prevalentemente sotto forma di cellule con citochine dal profilo Th2 che – dopo il contatto con le cellule B – producendo anticorpi, attivano la difesa contro batteri e tossine, ma in misura minore rispetto alle cellule T-4 helper con citochine dal profilo Th1 che, a loro volta, attivano cellule killer per attaccare con gas NO le cellule infette da funghi, virus e micobatteri.

le cellule T4 sono tra le più importanti del nostro Sist. Imm. , Romy in precedenza aveva detto che alcuni virus
producono sostanze che mimano l’azione dell’interleuchina 10 la quale inibisce le cellule T4 dal profilo Th1 che sono quelle che ci difendono dai virus,miceti,micobatteri; in pratica così avremmo il Sist. Imm. spostato più verso la difesa di batteri e tossine con pevalenza di T4 dal profilo Th2 e meno efficente nella lotta contro virus e miceti perchè verrebbero a mancare i T4 con prof. Th1.
per me questo è un ulteriore indizio a favore della causa virale ………..ma manca il nuovo virus……………
Non servirebbe un nuovo virus,basterebbe uno qualunque già attivo in precedenza nell’organismo che esce dalla latenza,che so’ anche un virus herpetico,tanto per dirne uno,ma anche altri virus valgono lo stesso,e se poi sono più di uno,allora è anche meglio.
É noto che, una volta contratto, il virus dell’herpes rimane nell’organismo per sempre, in forma latente, “rifugiato” nei gangli dorsali del sistema nervoso. Il mantenimento del virus nello stato di latenza è fortemente influenzato dalle condizioni di equilibrio o di disequilibrio del sistema immunitario.
Il controllo sul virus “silente”, e il mantenimento di questo nello stato di latenza, è esercitato da una componente specifica del sistema immunitario: si tratta dei linfociti T Helper di tipo 1 (TH1), aventi funzione di organizzare la difesa contro i virus (parassiti endocellulari obbligati) e contro altri microrganismi che si comportano in modo analogo. L’efficienza di queste cellule TH1 nei confronti del controllo del virus dell’herpes dipende dalle condizioni di equilibrio della “bilancia” immunitaria (figurativamente parlando, un “piatto” della bilancia è rappresentato dalla componente TH1, l’altro è invece costituito dai linfociti TH2, specializzati per rispondere ad “invasioni” da parte di microrganismi extracellulari e di antigeni di varia natura). La salute di un individuo, e l’assenza di manifestazioni sintomatiche, dipende dall’equilibrio esistente tra i due piatti della bilancia TH1 e TH2 e dalla prontezza di risposta, nei confronti dell’invasore, che da questo equilibrio dipende. È importante sapere che i due tipi di linfociti, TH1 e TH2, sono antagonisti, ossia producono entrambi delle sostanze (i mediatori chimici) con funzione inibitoria gli uni nei confronti degli altri. Il prevalere, ad esempio, dei TH2 comporta un abbassamento della risposta TH1 che, nel caso dell’herpes labiale, si traduce nell’incapacità di contenere efficacemente il virus in forma latente e di contrastare lo sviluppo di manifestazioni erpetiche recidivanti. L’herpes labiale ricorrente, infatti, come tutte le malattie virali, è una patologia favorita dalla diminuzione della risposta linfocitaria TH1 rispetto a quella TH2. Un fattore determinante nello spostare la bilancia immunitaria verso TH2 è rappresentato dal disequilibrio della flora batterica intestinale (disbiosi). Disbiosi significa scarsità di flora batterica intestinale benefica difensiva e sovraccrescita di microrganismi opportunistici e/o patogeni intestinali (candida, enterobatteri, ecc.) che, per la loro natura di “invasori” extracellulari, stimolano la proliferazione dei linfociti TH2, a scapito dei TH1, indebolendo ancor più le difese nei confronti dei virus erpetici. La disbiosi crea anche (ecco il legame tra herpes e intolleranze!) il presupposto per la genesi delle intolleranze alimentari: la mancanza di un’adeguata protezione microbica della mucosa intestinale, e la conseguente proliferazione dei patogeni, innesca infatti il progressivo logorio dell’integrità microbica ed anatomica della barriera filtrante selettiva intestinale, consentendo l’ingresso nell’organismo di macromolecole indigerite e di tossine (coloranti, conservanti, metalli pesanti, ecc.), che, essendo antigeni extracellulari, stimolano a loro volta l’attivazione dei TH2, a scapito dei TH1. Come se ciò non bastasse, l’organismo, costantemente “avvelenato” dall’ingresso di antigeni e tossine, entra in uno stato d’infiammazione cronica crescente che indebolisce ancora di più le capacità di difesa del sistema immunitario. L’organismo intossicato è sempre meno in grado di contenere il virus dell’herpes in fase latente: le recidive sono perciò sempre più frequenti. In situazioni di questo genere l’eliminazione degli alimenti cui si è intolleranti (sempre se si è riusciti a stabilire con esattezza quali essi siano) non porta alla risoluzione definitiva del problema. Il miglioramento iniziale, determinato dall’abbassamento dello stato infiammatorio cronico dell’organismo, non si mantiene nel tempo; la ragione di ciò sta nel fatto che, sino a quando la mucosa intestinale rimane compromessa, l’organismo inevitabilmente entra in contatto con le macromolecole degli alimenti utilizzati in sostituzione, sviluppando “nuove” intolleranze (ad esempio un soggetto intollerante al grano diventerà, nel giro di qualche mese, intollerante al farro e al kamut, utilizzati in alternativa). Ad un tipo di intossicazione ed infiammazione cronica dell’organismo ne fa perciò seguito un’altra, ostacolando il riequilibrio della bilancia TH1/TH2 e impedendo il contenimento del virus dell’herpes nella fase latente. In questa situazione, l’approccio nei confronti dell’herpes labiale recidivante prevede perciò necessariamente il ripristino dell’integrità anatomica e microbica della barriera intestinale, condizione indispensabile per la costruzione di un terreno individuale in grado di contrastare efficacemente le recidive.Ho scritto del virus erpetico,ma c’e ne sono a decine volendo,che è la stessa cosa.Pero’ capirai che detto così,le cause sono sempre più di una,centrano i virus,ma anche l’intestino ecc.ecc.

 

ECHINACEA

 3) ECHINACEA
ECHINACEA
(Angustifolia o Purpurea)

ECHINACEA

FAMIGLIA: Asteraceae

HABITAT: originaria del Nord America, viene oggi estesamente coltivata anche nell’Europa temperata in posizioni soleggiate.
PARTE  USATA: le sommità fiorite e le radici.
PREPARAZIONI  FARMACEUTICHE CONSIGLIATE: estratto secco titolato in echinacoside min. 0,6% (Farm. Francese X), la cui dose giornaliera va da 8 a 12 mg. per kg di peso corporeo, suddivisi in due somministrazioni da assumere preferibilmente lontano dai pasti.
COMPOSIZIONE  CHIMICA: è ricca di acidi organici e di composti alifatici insaturi, soprattutto alchilamidi e isobutilamidi di acidi polienici, presenti specialmente nelle radici. Contiene anche acidi grassi a catena lunga, polisaccaridi complessi, molti fruttani, glicoproteine, alcalodi, poliine e  numerosi flavonoidi. Contiene anche olio essenziale, che rappresenta lo 0,1-0,2% del peso della pianta secca e infine numerosi sali minerali.
PROPRIETÀ  TERAPEUTICHE: Azione immunostimolante: ha una buona azione immunostimolante aspecifica confermata da prove sperimentali quali aumento della fagocitosi (capacità di inglobare batteri, virus e corpi estranei) dei globuli bianchi, della differenziazione dei globuli bianchi immaturi in globuli bianchi maturi, della produzione e dell’attività dei macrofagi e della produzione di interferone e di interleukine, che sono sostanze molto importanti per i processi immunitari.
Uno studio nel ratto ha valutato se la somministrazione cronica di estratto secco titolato di echinacea dalla giovinezza fino alla vecchiaia fosse capace di aumentare la longevità e il benessere delle cellule del sistema immunitario, dal momento che è noto che l’attività di queste cellule è fondamentale per la sopravvivenza e la longevità. Gli animali venivano nutriti con 2 mg al giorno di estratto di echinacea o con un placebo per tutta la loro vita ed erano tenuti e dieta libera. Dopo 10 mesi si valutava la sopravvivenza di questi animali, che era del 79% in quelli del gruppo placebo e del 100% in quelli del gruppo echinacea. Dopo 13 mesi i risultati di sopravvivenza erano del 46% nel gruppo placebo e del 74% in quello echinacea. Agli stessi tempi si valutavano le cellule del sistema immunitario. In particolare si è notato che le cellule NK (natural killer) erano più numerose e vitali sia nel midollo sia nella milza sia nel sangue periferico dei ratti del gruppo echinacea, mentre i globuli bianchi non differivano in modo significativo tra i due gruppi. Lo studio indica che la somministrazione prolungata di echinacea per la maggior parte della vita del ratto aumenta la sopravvivenza, probabilmente per un effetto positivo sulle cellule NK.
Sono stati fatti numerosi studi clinici su pazienti con sindrome influenzale o con faringotonsilliti, che hanno dimostrato che l’estratto secco titolato di Echinacea è in grado di ridurre significativamente sia i sintomi sia la durata della malattia alla dose di 900 mg. di estratto al giorno somministrato per bocca.
Studi fatti su bambini con la pertosse hanno evidenziato che l’echinacea è in grado di ridurre la durata della malattia a cinque giorni, attenuandone nettamente i sintomi.
Un altro studio comprendeva un gruppo di pazienti che mostravano un netto calo dei globuli bianchi e una sintomatologia di tipo influenzale, con un numero di globuli bianchi pari a 4350 prima della terapia. Dopo tre giorni di cura con estratto secco titolato di Echinacea i leucociti aumentavano a 5950 e il 55% dei pazienti non aveva più i sintomi della malattia.
Sono stati fatti 45 studi clinici per valutare l’efficacia e la tollerabilità dell’Echinacea sia come preventivo sia come curativo delle infezioni delle prime vie aeree. In totale sono stati coinvolti circa 4000 pazienti.
Per indagare l’aspetto curativo sono stati condotti 20 studi, la maggior parte dei quali non ha riscontrato un’efficacia dell’echinacea superiore a quella del placebo. 4 studi invece hanno trovato che questa pianta era superiore al placebo.
Per valutare l’aspetto preventivo sono stati effettuati 25 studi, i cui risultati medi sono i seguenti: nei gruppi trattati con echinacea l’incidenza di infezioni delle prime vie aeree è stata del 29,3% e in quelli placebo del 36,7%. Inoltre il tempo di guarigione dei soggetti che prendevano l’echinacea era significativamente più breve rispetto a quello osservato nei gruppi placebo. Effetti collaterali: sporadici casi di reazioni allergiche.
Azione cicatrizzante: ha una notevole azione cicatrizzante a livello cutaneo, dovuta soprattutto all’inibizione dell’enzima jaluronidasi, che attacca e distrugge gli acidi ialuronici indispensabili per garantire l’elasticità dei tessuti. Ciò assicura la stabilità degli acidi jaluronici, che possiedono una notevole attività protettiva e cicatrizzante.
Azione anti-infiammatoria: l’Echinacea aumenta la produzione di ACTH, che è l’ormone capace di stimolare il surrene, da parte dell’ipofisi anteriore.  L’ACTH fa aumentare la produzione surrenalica di glicocorticoidi, i quali sono dotati di una notevole azione anti-infiammatoria. Ciò spiega, almeno in parte, l’attività anti-infiammatoria della pianta. Essa sarebbe anche dovuta a inibizione dell’attività degli enzimi capaci di stimolare la produzione di sostanze endogene che provocano infiammazione.
• Azione prevalente: immunostimolante aspecifica, in particolare per la prevenzione delle malattie infettive delle prime vie aeree.

• Altre azioni: cicatrizzante cutanea, anti-infettiva.

• Indicazioni principali: prevenzione delle malattie infettive delle prime vie aeree, sia nell’adulto sia nel bambino.
EFFETTI  COLLATERALI: può dare allergia in pazienti con intolleranza alle Asteraceae, con presenza di anticorpi specifici della classe delle IgE. Va quindi usata con cautela in pazienti allergici.
CONTROINDICAZIONI: questa pianta è controindicata in pazienti che debbano seguire una terapia soppressiva del sistema immunitario perché colpiti da malattie autoimmuni quali ad esempio rtrite reumatoide, collagenosi, sclerosi multipla e altre ancora.
Se usata per periodi superiori a 8 settimane e a dosi elevate questa pianta può dare epatotossicità, per cui non dovrebbe essere usata in pazienti con evidente insufficienza epatica.
INTERAZIONI COI FARMACI: può potenziare l’effetto negativo sul fegato di farmaci epatotossici come steroidi anabolizzanti, amiodarone, metotrexate e ketoconazolo.
DATI TOSSICOLOGICI: Dosi per via orale in dose unica di 30 g per kg di peso al giorno di succo pressato di echinacea purpurea nel ratto non hanno determinato effetti negativi apprezzabili, così come la somministrazione di 8 g per kg di peso al giorno per 4 settimane sempre nel ratto non ha dato luogo a danni evidenti.
Può essere usata in gravidanza, durante l’allattamento e in età pediatrica a partire da 1 anno di età.
BIBLIOGRAFIA.
1. Bauer R. et al. TLC and HPLC analysis of Echinacea pallida and Echinacea angustifolia roots. Planta Med. 54, 426-430, 1988.
2. Maffei-Facino R. et al. Echinacoside and caffeoyl conjugates protect collagen from free radical-induced degradation: a potential use of Echinacea extracts in the prevention of skin photodamage. Planta Med. 61, 510-514, 1995.
3. Dorsch W. Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies. Z. Arztl. Fortbild (Jena) 90, 117-122, 1996
4. Scaglione F. et al. Efficacy in the tratment of the common cold of a preparation containing an Echinacea extract. Int. J. Immunother. 11, 163-166, 1996.
5. Parnham M.J. et al. Benefit-risk assesment of the squeezed sap of the purple coneflower (Echinacea purpurea) for long term oral immunostimulation. Phytomedicine 3, 95-102, 1996.
6. Mengs U. et al. Toxicity of Echinacea purpurea. Acute, subacute and genotoxicity studies. Arzneimittel Forsch. 41, 1076-1081, 1991.
7. Baetgen D. Treatment of acute bronchitis in children. A practice study with an immunostimulant from Echinacea purpurea. Therapiewoche Padiatrie 1, 66-70, 1988.
8. Hoheisel O. et al. Echinagard treatment shortens the course of the common cold: a double blind, placebo controlled clinical trial. Eur. J. Clin. Res. S, 261-268, 1997.
9. Grimm W. et al. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am. J. Med. 106, 138-143, 1999.
10. Melchart D. et al. Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch. Fam. Med. 7, 541-545, 1998.
11. Percival S.S. Use of echinacea in medicine. Biochem. Pharmacol. 60, 155-158, 2000.
12. Melchart D. et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst. Rev.(2):CD000530, 2000.
13. Gallo M. et al. Pregnancy outcome following gestational exposure to echinacea: A prospective controlled study. Arch. Intern. Med. 160, 3141-3143, 2000.
14. Schulten B. et al. Efficacy of Echinacea purpurea in patients with a common cold. A placebo-controlled, randomised, double-blind clinical trial. Arzneimittelforschung 51, 563-568, 2001.
15. Mullins R J. et al. Adverse reactions associated with echinacea: the Australian experience. Ann. Allergy Asthma Immunol. 88, 42-51, 2002.
16. Barrett B.P. et al. Treatment of the common cold with unrefined echinacea. A  randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(12):939- 46, 2002.
17. Taylor J.A. et al. Efficacy and safety of echinacea in treating upper respiratory  tract infections in children: a randomized controlled trial. JAMA. 290(21):2824- 30, 2003.
18. Cohen H.A. et al. Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. Arch Pediatr Adolesc Med. 158(3):217-21, 2004.
19. Yale S.K. et al. Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med. 164(11):1237-41, 2004.
20. Sperber S.J. et al. Echinacea purpurea for prevention of experimental rhinovirus colds. Clin Infect Dis. 38(10):1367-71, 2004.
21. Caruso T.J. et al. Treatment of the common cold with echinacea: a structured review. Clin Infect Dis. 40(6):807-10, 2005.
22. Heinen-Kammerer T. et al. Effectiveness of echinacin in therapy of chronic  recurrent respiratory disease. Gesundheitswesen. 67(4):296-301, 2005.
23. Brousseau M. et al. Enhancement of natural killer cells and increased survival of aging mice fed daily Echinacea root extract from youth. Biogerontology. 6(3):157-63, 205.
24. Turner R.B. et al. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med. 353(4):341-8, 2005.

Immunostimolo x CFS

2) Miglioramento del sistema immunitario per il trattamento di CFS e fibromialgia

Immunostimolo

Le immunoglobuline sono gli anticorpi.

E’ una molecola proteica, prodotta da speciali cellule del sistema immunitario dell’organismo come risposta alla presenza di agenti esterni in esso penetrati, come virus, batteri, protozoi, funghi, cellule tumorali o di tessuti, che vengono riconosciuti come estranei per la presenza sulla loro superficie di molecole dette antigeni. Gli anticorpi vengono prodotti nel sangue da un particolare tipo di cellule, le plasmacellule, derivanti dalla differenziazione dei linfociti B in presenza dell’antigene. La funzione degli anticorpi è quella di riconoscere l’agente estraneo e di renderlo inoffensivo, con modalità che possono essere varie.

Tipi di anticorpi e struttura
La forma della molecola di un anticorpo può essere rappresentata come una Y, formata da quattro catene proteiche (due ‘pesanti’ e due ‘leggere’): alcune porzioni della molecola sono uguali per tutti gli anticorpi, mentre altre sono caratteristiche di ciascun tipo di anticorpo e gli conferiscono proprietà specifiche. Gli anticorpi, definiti anche immunoglobuline, sono generalmente indicati con l’abbreviazione Ig; in base alle differenze di struttura e funzione, sono classificati in cinque classi, indicate con le lettere A, D, E, G e M. Le immunoglobuline IgM costituiscono il primo tipo di anticorpo che il neonato è in grado di produrre, e anche il primo tipo che, nell’adulto, viene sintetizzato in presenza di un’infezione; le IgG, o gammaglobuline, sono gli anticorpi predominanti nel siero e compaiono quando l’organismo viene esposto per la seconda volta a uno stesso antigene; le IgE sono gli anticorpi prodotti in seguito a reazioni allergiche; le IgA sono costantemente presenti nella saliva, nel tubo digerente e nel latte materno; il ruolo delle IgD è sconosciuto.

Modalità d’azione
Il riconoscimento di un antigene da parte di un anticorpo avviene in modo specifico grazie al fatto che la struttura dell’anticorpo è complementare a quella dell’antigene: ciò permette alle due molecole di legarsi in modo analogo alla combinazione di una chiave con la corrispondente serratura. Gli anticorpi, dopo avere riconosciuto le sostanze antigeniche poste su cellule estranee e dopo essersi legati a esse, possono neutralizzare queste cellule con due modalità: 1) mediante l’attivazione del sistema del complemento, cioè di proteine plasmatiche che ne perforano la membrana; 2) attivando particolari cellule sanguigne che inglobano e distruggono quelle intruse con un processo di fagocitosi.
Dopo essere stato a contatto con un dato antigene, l’organismo continua a produrre per un certo numero di giorni anticorpi specifici; dopo avere raggiunto un valore massimo, la produzione decresce e infine si arresta. In alcuni casi, l’organismo mantiene nel suo sangue alcuni anticorpi per quell’antigene: esso, cioè, resta immunizzato in modo permanente, il che si verifica, ad esempio, in alcune malattie come la varicella. La produzione di anticorpi nell’organismo può essere stimolata con l’inoculazione di vaccini.
I tipi di anticorpi che ogni organismo può sintetizzare è estremamente elevato, dato che elevato è il numero delle sostanze che si comportano da antigeni: in realtà, qualsiasi sostanza che viene introdotta nel corpo è estranea a esso e quindi può agire da antigene. Esistono alcune patologie in cui l’organismo non è più in grado di riconoscere come proprie alcune sue parti, e produce anticorpi contro di esse. Malattie di questo tipo sono in genere definite malattie autoimmuni e comprendono, ad esempio, il lupus eritematoso sistemico e la sclerosi multipla.

Anticorpi monoclonali
Un clone di linfociti B o di plasmacellule è costituito da un gruppo di cellule identiche, che producono un unico tipo di anticorpo, diretto contro uno specifico antigene. Tali proprietà vennero sfruttate nel 1975 da Cesar Milstein e Georges Köhler, che svilupparono una tecnica in cui alcuni linfociti B clonali, prelevati dalla milza di un topo, venivano fusi con cellule tumorali, dando luogo a cellule ibride, o ibridomi, in grado di produrre grandi quantità di anticorpo specifico (caratteristica del clone di linfociti), riproducendosi continuamente (caratteristica della cellula tumorale). Questi anticorpi, definiti anticorpi monoclonali, sono in breve tempo diventati un prezioso strumento diagnostico e di ricerca per biologi e medici. I comuni test di gravidanza venduti in farmacia agiscono, ad esempio, in base al riconoscimento, da parte di un anticorpo monoclonale, di un antigene presente nell’urina delle donne gravide. Per la messa a punto della tecnica di produzione degli anticorpi monoclonali, nel 1984 ai due ricercatori sopra citati è stato conferito il premio Nobel per la medicina o la fisiologia.

Uno studio controllato di G immunoglobuline per via endovenosa nella sindrome da stanchezza cronica. http://www.ncbi.nlm.nih.gov/pubmed/2239975
http://cid.oxfordjournals.org/content/36/9/e100.full.pdf
Immunoglobulina endovenosa è efficace nel trattamento di pazienti con sindrome da stanchezza cronica.
http://www.ncbi.nlm.nih.gov/pubmed/9236484
Immunostimolanti
Fonte: “da affaticato a Fantastic” da Jacob Teitelbaum, M.D.

• Proteina del timo-(aka – Proboost e Bio Pro A) – sciogliere il contenuto di 1 bustina sotto la vostra linguetta – qualsiasi che viene ingerito è distrutto! Prendere tre volte al giorno per 12 settimane, poi 1 al giorno per 6 settimane. Anche prendere 3 volte al giorno al primo segno di qualsiasi infezione fino a quando l’infezione si risolve (è circa $1,80 un pacchetto).Disponibile dal nostro ufficio (800 333 5287 o www.vitality101.com). Funziona nelle prime 24 ore per le infezioni acute, ma prende 2-3 mesi a lavorare per infezioni croniche.
• argento colloidale-(disponibile nel nostro negozio web o ingrosso da www.natural-immunogenics.com o 888 328 8840).Vedere # 75.
• _ Leuko-Stim (Ultraceuticals) – questo mix stimola principalmente la funzione immunitaria, ma le foglie di olivo possono anche avere proprietà anti-virali. Contiene Estratto di foglie di olivo, Beta 1,3 glucano, Maitake Mushroom Extract e arabinogalattano.
• Maitake d frazione 30 (Ultraceuticals) – con 330 mg di maitake mushroom extract (un eccellente stimolante immunitario).
• Gamma globuline – 2 cc IM 1-2 x settimana o 4 cc IM ogni 1-2 settimane per 6 settimane, poi come stati necessari. Può “jump start” il sistema immunitario. Costi ~ $38 per dose di 2 cc.
• ImmPower – capsule da 500 mg – prendere 2 capsule 3 volte al giorno per 3 settimane. Quindi prendere 1 due volte al giorno.Questo prodotto naturale triple alcune componenti importanti (natural killer cells) del sistema immunitario. È costoso.
• Isoprinosine (inosina pranobex) – 500 mg compresse: settimane 1, 3, 5, 7, 9 e 11 prendono 2 schede 3 x giorno Lunedi al venerdì. Settimane 2, 4, 6, 8, 10 e 12 prendono 2 compresse al mattino lunedì-venerdì.

Altri Immunostimolanti naturali

Echinacea
Uncaria tormentosa

MCS

La sensibilità chimica multipla, in inglese Multiple Chemical Sensitivity (MCS), secondo la definizione che ne dà il National Institute of Environmental Health Sciences statunitense, è una malattia causata dall’impossibilità di una persona a tollerare un dato ambiente chimico o una classe di sostanze chimiche.
Spesso confusa con allergie di vario genere, con disurbi psichiatrici, del comportamento, si manifesta disturbi soggettivi della salute, simili nella MCS e in numerose altre condizioni simili, come la spossatezza, il dolore muscolo-scheletrico cronico, comuni nella sindrome da affaticamento cronico e nella fibromialgia.
Questi disturbi sono basati su sensazioni che per la maggior parte delle persone rientrano tra i normali processi fisiologici; in alcuni individui queste sensazioni diventano intollerabili.
Le persone cui è stata diagnosticata una MCS dichiarano di soffrire di disturbi estremamente vari, generici ed aspecifici; non esistono infatti due pazienti che presentano i medesimi sintomi o la medesima risposta ad una stessa sostanza o situazione, aspetto che contribuisce a renderne ulteriormente dubbia la reale esistenza come patologia organica riconoscibile.
Sintomi comunemente lamentati nella MCS sono spesso aspecifici:
 difficoltà respiratorie, dolori toracici e asma
 irritazione della pelle, dermatiti da contatto, orticaria ed altre forme di eruzione cutanea
 emicrania
 astenia marcata e non spiegabile in alcun modo, senso di affaticamento e letargia
 “annebbiamento mentale” (amnesia a breve termine, disfunzioni cognitive)
 modificazioni della personalità acute ed improvvise (attacchi di panico, fobie, aggressività immotivata)
 difficoltà digestive, nausea, indigestione, bruciore di stomaco, vomito, diarrea
 multiple intolleranze a cibi, più o meno clinicamente identificabili (ad esempio intolleranza al lattosio e celiachia)
 dolore ai muscoli e alle articolazioni
 vertigine e capogiro
 senso dell’olfatto ipersensibilizzato, ipersensibilità alle fragranze vegetali (terpeni) e di origine sintetica
Tali sintomi si accompagnano spesso a depressione e stati ansiosi.
Le persone affette da Mcs non possono stare a contatto con una lunghissima lista di sostanze e oggetti tra cui solventi, vernici, colla, combustibili e gas di scarico delle auto, pesticidi, fungicidi, insetticidi, materiale di arredo nuovi, produzioni di legno, detersivi, cloro, ammoniaca, articoli profumati, materiale odontoiatrico, disinfettanti, gas anestetici, medicamenti e odori vari di cibi e bevande.
Le terapie disponibili in Medicina Integrata si avvalgono di varie procedure di disintossicazione, mediante rimedi omeopatici e fitoterapici, di sostegno ai principali organi emuntori(fegato, reni, pelle), della supplementazione di vitamine, antiossidanti, prodotti antinfiammatori di origine naturale, dieta con cibi di origine biologica certificata, uso di vestiti privi il più possibile di sostanze chimiche non tollerate, ma la principale misura che ad oggi i malati debbono sempre tenere presente è l’evitamento dei luoghi che percepiscono come non salutari.

Immune Assist

Immune Assist

1) IMMUNE-ASSIST™ Research Summary
Medicinal Mushroom Polysaccharide Blend – Immune Enhancing Complex
Research Summary

SEPTEMBER 19, 2009

MEDICINAL MUSHROOM EXTRACTS: ONE OF THE MOST POWERFUL IMMUNE MODULATORS KNOWN
Recent scientific research has shown that medicinal mushrooms grown on vegetable sources (such as millet, rice bran, buckwheat, barley, etc.) enzymatically activate a process whereby complex cross-linked polysaccharides from the vegetable sources are converted to biologically active immunomodulators (also known as biological response modifiers). As you will see from the discussion below, the polysaccharides produced by this process are effective and safe immune stimulants.
Medicinal mushroom research has focused on discovering compounds that can modulate positively or negatively the biological response of immune cells. Certain mushroom derived-glucans and polysaccharide-bound proteins have been shown to act as immunomodulators or biological response modifiers (BRMs), where these polymers interact with the immune system to upregulate or downregulate specific aspects of the responses of the host and this may result in various therapeutic effects. Whether certain compounds enhance or suppress immune responses can depend on a number of factors including dosage, route of administration, timing and frequency of administration, mechanism of action or the site of activity. Many mushroom-derived polysaccharides appear to fit the accepted criteria for BRM compounds. They cause no harm and place no additional stress on the body, they assist the body to adapt to the various environmental and psychological stresses, and they have a non-specific action on the body, supporting all the major systems, including nervous, hormonal, and immune systems, as well as regulatory functions.
The anti-tumor polysaccharides isolated from mushrooms (fruit-body, submerged, cultured mycelial biomass or liquid culture broth) are either water-soluble β-D-glucans, β-D-glucans with heterosaccharide chains of xylose, mannose, galactose, or uronic acid or β-D-glucan-protein complexes – proteoglycans.
While the role of medicinal mushrooms in immunomodulation and anti-cancer activities represents the central theme of much of the conducted research, it is pertinent to observe that many of the medicinal mushrooms have been highly valued for other medicinal properties including hypercholesterolemia, high blood pressure, diabetes, anti-viral, anti-bacteria, and antioxidant and free radical scavenging.
The safety criteria for mushroom-derived β-glucans have been exhaustively carried out in pre-clinical experiments. Acute, subacute, and chronic toxicity tests have been carried out together with administration during pregnancy and lactation with no adverse effects. There were no anaphylactic reactions and no effects in mutagenicity and haemolysis tests, blood coagulation and a wide range of other regulatory tests. There was no evidence of genotoxicity. Similar results have been obtained with other β-glucans. When applied to humans in Phase 1 clinical tests, the β-glucans demonstrate remarkably few adverse clinical reactions.
In the 2001 report Medicinal Mushrooms: Their Therapeutic Properties and Current Medical Usage with Special Emphasis on Cancer Treatments, a wide variety of mushroom polysaccharides, including Lentinan (from L. edodes), Schizophyllan (from S. commune), PSK and PSP (from Trametes versicolor), and Grifron-D (from the Maitake mushroom G. frondosa) and others are described, and their properties are shown to satisfy the criteria for BRMs. Many of these mushroom-derived polymers potentiate the host’s innate (non-specific) and acquired (specific) immune responses in a similar manner, where they activate many kinds of immune cells that are vitally important for the maintenance of homeostasis. Key innate responses that are stimulated by these mushroom derived-β-glucans or polysaccharide-protein complexes include host T-cells (such as cytotoxic macrophages, monocytes, neutrophils, natural killer cells, and dendritic cells) and chemical messengers (cytokines such as interleukins, interferon and colony stimulating factors) that trigger complement and acute phase responses. Moreover, mushroom polysaccharides or polysaccharide-protein complexes are considered as multi-cytokine inducers that are able to induce gene expression of various immunomodulatory cytokines and cytokine receptors. In addition, acquired responses are also enlisted, where lymphocytes that govern antibody production (B cells) and cell-mediated cytotoxicity (T-cells) are stimulated. While the immune system is shrouded in tremendous complexity, our current understanding shows that it is regulated in an orchestrated dynamic manner.
Mushroom-derived polysaccharides have shown anti-tumour activities in both pre-clinical models and in clinical trials. Although the mechanism of their anti-tumour action is still not completely clear, Lentinan, Schizophyllan, PSP, PSK and other mushroom polysaccharides appear to mediate their anti-tumour activity by activation or augmentation of the host’s immune system (via stimulated cytotoxic macrophages, cytotoxic T-cells and antibody-mediated cytoxicity of targeted cancer cells), rather than direct cytotoxicity. Thus, both cell-mediated immune responses against the target T-cells initiated by macrophage-lymphocyte interactions and cytoxicity induced by antibodies to target T-cells are believed to contribute to the elimination of targeted tumour cells. Recent evidence suggests that several mushroom polysaccharides may also possess cytotoxic properties. Grifron-D from G. fondosa mushroom was reported to induce apoptosis (programmed cell death) in human prostate cancer cell-lines.
IMMUNE-ASSIST™ DAILY FORMULA INCORPORATES POLYSACCHARIDE EXTRACTS FROM SIX MEDICINAL MUSHROOMS
In China , Japan , Korea and more recently in the USA hundreds of mushroom species have been studied during the past 20 years.  Extracts from most of the medicinal mushrooms show a common property of enhancing immune function by modulating cell-mediated immunity.  Simply put, such mushroom extracts seem to turn on cells in the immune system, which appear to have significant disease-fighting properties.  In fact, three different anticancer drugs extracted from mushrooms have been approved by the Japanese equivalent of FDA (that is, the Japanese Health and Welfare Ministry). These three are lentinan, derived from shiitake; PSK, derived from coriolus versicolor; and schizophyllan, derived from suehirotake.
Based on the latest research a USA-based company (Aloha Medicinals, Inc.) has formulatedIMMUNE-ASSIST™ Daily Formula – a combination of more than 200 different polysaccharides, derived from the enzymatic breakdown of complex organic plant material from six different species of medicinal mushrooms. These include Agaricus blazei, Cordyceps sinensis hybrid, Lentinula edodes (shiitake), Grifola frondosa (maitake), Ganoderma lucidum (reshi), and Coriolus versicolor. IMMUNE-ASSIST™ Daily Formula contains simple polysaccharides similar to many other products on the market, but it also contains much more complex polysaccharides like the cross-linked beta mannans and beta-glucans, as well as hetero-polysaccharides which combine both alpha- and beta-bound monosaccharides into the same molecule. This is why Immune-Assist™ shows such a greater range of immuno-modulation bioactivity than other bran based supplements. Included among the important substances in Immune-Assist™ are Arabinoxylane, Lentinan, Grifolan (Dr. Nanba’s original Maitake D-Fraction), PSK and PSP, and Active Hemicellulose Correlated Compound (AHCC).
Below we provide a brief summary of the research and clinical studies for each of the mushrooms contained in IMMUNE-ASSIST™ Daily Formula:
Shiitake is now the most popular and most cultivated exotic mushroom in the world. In China, shiitake has a history that dates back to the Ming Dynasty (1368-1644 ACE).  The mushroom was used not only as a food but was taken as a remedy for upper respiratory diseases, poor blood circulation, liver trouble, exhaustion and weakness, and to boost chi, or life energy.  It was also believed to prevent premature aging.  Today the shiitake is recognized for its antitumor action and has been extensively researched in regard to its immunologic activity.  The initial antitumor research was performed in 1969 by Tetsuro Ikekawa at Purdue University, along with colleagues at the National Cancer Center Research Institute in Tokyo.  The researchers found that water extracts of shiitake produced high rates of tumor inhibition in mice (72 percent to 92 percent).  Ikekawa later identified a polysaccharide in shiitake called lentinan as having powerful antitumor activity.
Coriolus (or Trametes) versicolor is the most thoroughly clinically researched mushroom. An extract of Coriolus versicolor known as PSK is sold in Europe and Japan. It is the best-selling cancer drug in the world and recently accounted for more than 25% of Japan’s total national expenditure for anticancer agents. In addition to possessing many different antitumor properties, it is also an immunostimulant; demonstrates anti-viral activity; enhances T-cell proliferation; and has been shown to improve both disease-free and survival rates in cancer patients. In an 8-year clinical test of breast cancer patients, and in another 5-year study, it was shown that the polysaccharide compounds contained within Coriolus versicolor work particularly well as an adjuvant for cancer therapies, exhibiting diverse biological activities.
Maitake may be even more potent than any of the other mushrooms previously studied. This legendary giant mushroom has been studied for its anticancer, anti-diabetic, anti-hypertensive and anti-hyperlipemic effects since the mid-1980s. Its anti-HIV activity in vitro was demonstrated in tests conducted by the Japan Institute of Health and the U.S. National Cancer Institute in early 1992.  Among various extracts obtained from the Maitake mushroom, a specific extracted fraction named Maitake D-fraction is the active constituent. This extract contains beta-1, 3-glucans and beta-1, 6-glucans protein-bound polysaccharides. It has demonstrated remarkable antitumor activity by activating the immune system through oral administration.
The Chinese have long used Cordyceps sinensis to promote overall good health, and modern research indicates that it does indeed support liver, kidney, heart, and immune system function. Cordyceps sinensis has been used to protect the bone marrow and digestive systems of mice from whole body irradiation. One experiment noted that Cordyceps may protect the liver from damage. An experiment with mice indicated the mushroom may have an anti-depressant effect. Researchers have observed that Cordyceps has a hypoglycemic effect and may be beneficial for people with insulin resistance. Cordyceps mushroom extracts have been shown to stimulate the number of T helper cells, prolong the survival of lymphocytes, enhance TNF-alpha and interleukin 1 production, and increase the activity of natural killer cells. One study indicates that cordyceps can stimulate progesterone production in animal cells. Another study has shown that cordyceps may be effective against tumor cells by down-regulating MHC class II antigen expression. In addition, historical use data suggests that cordyceps can cause a reduction of cyclosporin and aminoglycoside-induced renal toxicity.
Reishi possess anti-tumor, immunomodulary, and immunotherapeutic activities, supported by studies on polysaccharides, terpene, and other bioactive compounds isolated from fruiting bodies and mycelia of this fungus. It has also been found to inhibit platelet aggregation, and to lower blood pressure (via inhibition of angiotensin-converting enzyme), cholesterol and blood sugar. Laboratory studies have shown anti-neoplastic effects of fungal extracts or isolated compounds against some types of cancer. In an animal model, Reishi has been reported to prevent cancer metastasis, with potency comparable to Lentinan from shiitake mushrooms. The mechanisms by which Reishi affect cancer may target different stages of cancer development include: 1) inhibition of angiogenesis (formation of new, tumor-induced blood vessels created to supply nutrients to the tumor) mediated by cytokines, 2) cytotoxicity, 3) inhibition of migration of the cancer cells and metastasis, and 4) inducing and enhancing apoptosis of tumor cells. Besides effects on mammalian physiology, Reishiis reported to have anti-bacterial and anti-viral activities. Reishi is reported to exhibit direct anti-viral effects with the following viruses: HSV-1, HSV-2, and influenza.
Agaricus blazei is an edible mushroom native to Brazil and cultivated in Japan and the USA for its medicinal uses. It has been used to treat arteriosclerosis, hepatitis, hyperlipidemia, diabetes, dermatitis, and cancer. In vitro experiments and studies done in mice have shown that Agaricus has immunomodulatory, antitumor, and antimutagenic properties. The polysaccharides and anti-angiogenic compounds present in Agaricus are thought to be responsible for its antitumor properties. Such effects are believed to be exerted by immunopotentiation or direct inhibition of angiogenesis. A recent randomized study showed that oral administration of Agaricus extract improved the natural killer cell activity and quality of life in gynecological cancer patients undergoing chemotherapy. Agaricus was also shown to have antidiabetic effects in vitro and in animal studies. In addition, results from a study done in human subjects with type 2 diabetes suggest benefits of Agaricus extract in improving insulin resistance, and a pilot study indicates that Agaricus extract may reduce weight, BMI, body fat, and serum glucose and cholesterol levels in healthy individuals.
AHCC AS A COMPONENT OF IMMUNE-ASSIST™ DAILY FORMULA
AHCC is produced by from the enzymatic action of vegetable sources with mycelial extracts from several different mushrooms. There is about four times more AHCC in each dose ofImmune-Assist™ than there is in other AHCC products on the market.
AHCC is a food substance that contains a broad range of polysaccharides. It is believed that a special polysaccharide with a molecular weight of about 5,000 and an alpha 1,4 glucan linkage in this mushroom extract is primarily responsible for the powerful immune enhancing effects on natural killer cells. A heavier polysaccharide in the extract appears to have a powerful stimulating effect on macrophages which, in turn, further stimulates the immune system including a number of cytokines (Interleukin-2, Interleukin-12, Tumor Necrosis Factor [TNF], and Interferon).  Furthermore, some research has indicated that components of AHCC may have direct cytotoxic effects on cancer cells and prevent metastases from occurring.
NATURAL KILLER CELLS
The human immune system is comprised of more than 130 subsets of white blood cells. Natural Killer (NK) cells make up roughly 15% of all human white blood cells. They provide the first line of defense for dealing with any form of invasion to the body. Each NK cell contains several small granules that act as chemical destroyers. Once an NK cell has recognized a cancer cell, for example, it attaches itself to the cell’s outer membrane and injects these granules directly into the interior of the cell. The granules then destroy the cancer cell within five minutes. The undamaged NK cell then moves on to other cancer cells and repeats the process. When the immune system is particularly strong, active NK cells will often take on more than one cancer cells or other infected cells at the same time.
NK CELL ACTIVITY, NOT NUMBER, DETERMINES THE STRENGTH OF THE IMMUNE SYSTEM
Unlike other white blood cells, inadequate numbers of NK cells are very rarely a problem. Instead, it is the activity of the cells that generally determines whether one is sick or healthy. As long as the NK cells are active, everything remains under control. If NK cells lose their ability to either recognize or destroy the invader, however, the situation can deteriorate rapidly. In AIDS and cancer patients, NK cell activity is probably the primary criteria for estimating the chances of survival. It’s commonly accepted that when NK cells cease to function, the end is near.
In addition, research has now confirmed that individuals with low NK cell activity are significantly more susceptible to autoimmune diseases, chronic fatigue syndrome, viral infections and the development of cancerous tumors.
Doctors can test NK cell activity with a test called the NK cell function test. Basically, a blood sample is taken from the patient and placed in a vial containing live tumor cells. After four hours, a count is taken to determine what percentage of the cancer cells have been destroyed by the NK cells. The higher the percentage, the more active the cells. This test is referred to as the 4 hour Chromium-release assay. Your doctor can order the test from Immune Sciences Lab in Beverly Hills, CA at 310-657-1077.
HOW IMMUNE-ASSIST™ DAILY FORMULA INCREASES NK CELL ACTIVITY AND IMMUNITY
The capacity of Immune-Assist™ to boost NK activity and overall immunity appears to stem from the following:
1) Immune-Assist™ increases the number of explosive granules in NK cells. The more granules an NK cell carries, the more cancer and virus-infected cells it can destroy,
2) Oral ingestion of Immune-Assist™ can increase NK activity as much as 300% (or even higher),
3) It increases interferon (IFN) levels. Interferon is another potent compound produced by the body that both inhibits the replication of viruses and other parasites and increases NK cell activity,
4) Immune-Assist™ increases the formation of Tumor Necrosis Factors (TNFs). TNFs are a group of proteins that help destroy cancer cells,
5) It increases number and the activity of other lymphocytes, especially T-cells (up to 200%) and macrophages,
6) It stimulates cytokine (IL-2, IL-12, TNF, and IFN) production, which stimulates immune function.
CANCER
Unlike most forms of cancer treatment, Immune-Assist™ is totally non-toxic.  After years of use and continued toxicity tests, there has never been any indication of toxicity or side effects whatsoever.  Most likely, this is because Immune-Assist’s primary function is to enhance the activity of the immune system rather than to attack cancer cells directly. This also helps explain why it seems to work well for all types of cancer.
IMMUNE-ASSIST™ HELPS CANCERS THAT ARE UNAFFECTED BY ANGIOGENESIS INHIBITORS
Immune-Assist™ fills a gap left by many of the other natural therapies, in particular, the class of therapies known as angiogenesis inhibitors.  Angiogenesis inhibitors work by cutting off the blood supply to tumors. Whether they are natural products like shark cartilage or pharmaceutical ones like endostatin and angiostatin, these angiogenesis inhibitors aren’t very effective at treating blood cancers such as leukemia, lymphatic cancer or lung cancer.
Because leukemia is a cancer of the blood cells themselves, cutting off the blood supply to these cells is impossible. With lymphatic cancer, it’s the lymphatic fluids, not blood vessels, that supply lymph cells with all of their necessary nutrients, so again, cutting off the blood supply is useless. Also, because the lungs have such a rich and complex supply of blood vessels, there is no effective way to restrict blood flow to that area.
None of these factors prevent Immune-Assist™ from doing its job. By increasing the activity of NK cells, which naturally reside and circulate in the blood and lymph systems, Immune-Assist™ can be used effectively for all of these cancers. The NK cells don’t have to penetrate deep into massive hard tumors to get to active cancer cells—they simply identify and eliminate the cancer cells they “encounter” in the blood or lymph.
IMMUNE-ASSIST BRAND DIETARY SUPPLEMENT AS AN ADJUNCT FOR CHEMO AND RADIATION THERAPY IN CANCER.
A clinical trial conducted between August 2000 and April 2001 at the People’s Hospital of Lishui City, Zhejiang Province, People’s Republic of China, showing the clinical manifestations of a mixture of six Medicinal Mushroom extracts as an adjunct therapy to improve the immune function of cancer patients undergoing other therapies. Methods: the Zhejiang Qingyuan Fungi Medicinal & Health Products Co., Ltd produced the experimental mixture used in this clinical trial. This mixture was formulated and is marketed in the United States of America under the trade name Immune-Assist where it has shown good results in cancer treatment. This mixture includes Alpha and Beta-Glucans and other polysaccharides, extracted from the following well-known species of medicinal mushrooms: Agaricus blazei (polysaccharide >40%), Lentinus edodes (polysaccharide >25%), Grifola frondosa (polysaccharide >28%), Ganoderma lucidum (polysaccharide >20%), Coriolus versicolor (polysaccharide >30%), and Cordyceps sinensis mycelium (polysaccharide >30%).
These six extracts were mixed together into tablet form and co-administered along with chemotherapy or radiation therapy to the patients undergoing treatment as a daily regimen. This trial was conducted among 56 cancer patients, 30 chosen to receive the Medicinal Mushroom extract mix and another 26 comparable patients as a control group, receiving the accepted pharmaceutical drug Polyactin-A ™ as a control group. All patients were in the middle-late stages (Stage 3 and 4) of cancer. Polyactin-A is made by Taixing Medicine Company, Ltd. in Chengdu, PRC and the lot number used was 20000327. Results: There are significant differences between the experimental group and the control group. The experimental group of patients had improvements in the disease progression and Quality of Life measurements as compared to the control group of cancer patients. Discussion: This formulation of mixed polysaccharides, made up from the six species of Medicinal Mushrooms named, has great potential as a new health product for the improvement of immunity and showing high effectiveness and non-toxicity for use in cancer patients undergoing conventional therapy.
CLINICAL TRIAL RESEARCH ON IMMUNE–ASSIST ™ BRAND DIETARY SUPPLEMENT FOR THE TREATMENT OF ALCOHOLIC LIVER DISEASE AND HYPERLIPIDEMIA
A clinical trial was conducted using Immune–Assist Brand mushroom extract mixture for the treatment of Alcoholic Liver Disease and hyperlipidemia. Through this study the preparation method, the quality control standards, the medicinal function and the safety and toxicity study, it was found that this preparation was both safe and effective, and shows great potential as a preventive and health care medicine for treating and curing the disease of alcoholic liver and hyperlipidemia. We found that this polysaccharide mixture could not only restrain the alcohol-induced damage to the liver cells, but also enhances the restoration of liver function and decreases blood lipids. The results were significant and safe. This compound shows great promise for use in clinical therapy.
Alcohol is used widely throughout society, and often for medicinal purposes such as to stimulate the appetite, cure pain, and eliminate fatigue and as a disinfectant. But alcohol use is more often indicated in health problems, for example a wide range of acute and chronic diseases and behavioral dysfunction. Chronic alcoholism has become a global social problem. In America alone, an estimated 100,000 people die annually due to the abuse of alcohol. The economic burden in this one country is estimated to be about 100 billion dollars a year. Chronic alcoholism has become a familiar disease in many other countries as well. Because of this, many experts at home and abroad have been studying effective ways to restrain the damage to liver cells caused by chronic abuse of alcohol, and ways of treating or curing the fibrosis of the liver resultant of chronic alcohol abuse. In recent years, science has found that the polysaccharides extracted from edible mushrooms have various biologically active functions. The city of Lishui, which lies in the southwest of the Zhejiang province of China, has a rich resource of edible mushrooms, and a long history of the use of medicinal mushrooms. A thorough review of the literature and customs of this area has shown that these mushrooms can protect the liver, decrease blood lipids and improve immune function. According to this long history of folk-usage, a modern extraction method was developed to produce an effective medicinal mushroom polysaccharide combination. This mushroom extract combination is marketed in America under the brand name Immune-Assist Critical Care Formula by Aloha Medicinals Inc. The components of this formula are alcohol precipitated hot water extracts of Lentinula edodes, Grifola frondosa, Coriolus [Trametes] versicolor, Agaricus blazei, Ganoderma lucidum, Cordyceps sinensis, and the extra-cellular compounds derived from the spent culture broth of liquid-fermented Cordyceps sinensis. From April of 2001 to May of 2002, this research group used the Immune-Assist formula in the treatment of alcoholic liver disease and hyperlipidemia. The tablets used in this study were 500 mg each of active ingredients containing 400 mg mixture of very complex polysaccharides, mainly (d)beta-glucans of differing structures, primarily 1↔3 main chain structure with 1↔6 side branching. With more than 200 differing polysaccharide structures, there are many other polysaccharides present besides these prototypical and well-understood mushroom-derived immunomodulator compounds. The PRC government research authorization number granted to this project was 99-118. The primary research results are as follows.
Each tablet contains 500 mg mixture of active ingredients consisting of equal parts of the following: Lentinula edodes polysaccharides (Lentinan), Grifola frondosa polysaccharides (Maitake D-Fraction), Trametes versicolor protein-bound polysaccharides (PSK and PSP), Cordyceps sinensis Polysaccharides and exo-polysaccharides, Agaricus blazei Polysaccharide and Ganoderma lucidum polysaccharides. These polysaccharides were extracted from full spectrum mycoproducts grown by sterile tissue culture using a proprietary two step extraction and purification process consisting of extraction with hot water, repeated 4 times at 98-99 degrees C, concentration of the water extract portion under reduced pressure, then addition of 4 times the volume of pharmaceutical grade ethanol, which causes the purified polysaccharides, protein bound polysaccharides and heteropolysaccharides to precipitate from the solution, thus separating the alcohol soluble portion. The precipitated polysaccharide compounds are then collected and spray dried. This purified protein-polysaccharide complex is blended with pharmaceutical binders and excipients to manufacture tablets as per usual protocols used in tableting.
All the results gathered suggest that the mushroom polysaccharide combination Immune-Assist has apparent and profound function in decreasing the blood cholesterol and triglycerides, and at the same time has obvious effect for the chemical protection and repair of the damaged liver. Edible mushrooms have many good medicinal functions and bio-active compounds and can improve the patient’s overall resistance and disease dormancy period, increase the appetite, ameliorate fatigue, regulate and enhance the patient’s immunity, etc. By consuming these mushrooms the body’s nonspecific immunity is enhanced, there is a measurable improvement in the secretion of IgA, an increase in the function of mononuclear-phagocytes and in the activity of the NK cells, regulation of the immune balance, resistance to the alcoholic damage of liver cell efficiency and acceleration of the restoration and regeneration of damaged liver tissue cells. This study shows that edible fungi have certain curative effect on chemically induced liver damage and in blood fat reduction. Edible fungi can play an important role in the clinical treatment for these conditions.
CLINICAL TRIAL REPORT ON TREATMENT OF CHRONIC HEPATITIS B USINGIMMUNE-ASSIST™ BRAND DIETARY SUPPLEMENT AS ADJUNCT WITH LAMIVUDINE[EPIVIRTM]
Presented here are the results of a study conducted on 60 patients with chronic hepatitis B over a two year period, evaluating the value of adding proprietary Immune-Assist™ brand of medicinal mushroom polysaccharide mixture as an adjunct to conventional therapy in order to achieve greater effectiveness than can be provided by the conventional therapy alone.
In recent years it has been found that the polysaccharides extracted from edible fungi have various biological activity functions, including immune enhancement. The city of Lishui, which lies in the south-west of Zhejiang province, is one of the major mushroom cultivation districts in China and has rich resources of these edible fungi. It is a long-standing tradition for the populace of this area to use the edible fungi as part of their medicine. While researching the traditional medicine and folk recipes of the people of this area, there is found a widespread belief that edible fungi can protect the liver, reduce obesity and improve overall immunity. In accordance with this traditional belief, this study was conducted using modern extraction methods in the preparation of a mushroom polysaccharide mixture according to the formula ofImmune-Assist Critical Care Formula™, a proprietary health supplement developed as a joint project between the Government of Zhejiang province and a privately held American company, Aloha Medicinals Inc. This mixture is manufactured and distributed in the United States of America by Aloha Medicinals Inc. The formula is composed of alcohol precipitated hot water extracts of six species of medicinal mushrooms: Lentinula edodes, Agaricus blazei, Grifola frondosa, Coriolus [Trametes] versicolor, Ganoderma lucidum and two types of Cordyceps sinensis extracts, one from the mycelium and one from the culture broth of liquid-fermented Cordyceps sinensis. We tested this mixture concurrently with the accepted druglamivudine in the cure of chronic hepatitis. With lamivudine therapy alone, the rate of hepatitis Be antigen converting from positive to negative is 10%-20% with a full years’ course of therapy, and this antibody sero-conversion to negative increases by continuous use oflamivudine continuously year after year. Because of this long period of treatment, there is concern that the virus will induce genetic variation, as well as some patients discontinuing the therapy after time due to economic hardship. From February 2000 to August 2001, our research group used this mushroom polysaccharide formula and lamivudine together to treat hepatitis B for 9 months. From April in 2001 to May in 2002, the research group used this mushroom polysaccharide tablet and lamivudine together to treat hepatitis B compounded with hyperlipidemia with good results. The PRC government clinical trial sanction number for this trial is 99-118. Each tablet contains 500 mg total active ingredients derived from the six species of mushrooms, of which 400 mg consists of amylase reactable polysaccharides. The primary research results are as follows: After 9 months of treatment, a comparison of the rate of hepatitis antibodies converting from positive to negative showed 20 cases of HBeAg in the experimental group convert to negative (62.5%), while only 8 cases of HbeAg in the comparison group convert to negative (28.6%). The sero-conversion rate of these two groups is significant. From this trial we find that the mushroom polysaccharides can play an important roll in curing hepatitis B, and this mushroom polysaccharide mixture (Immune-Assist) should be considered as an adjunct to conventional hepatitis treatment.
IMMUNE-ASSIST™ DAILY FORMULA AS AN ADJUCT IN PROTOCOLS FOR LYME DISEASE
In many countries where Lyme disease occurs there are available prescription drugs which act in conjunction with antibiotics to increase the curative potential of the antibiotic therapy. These drugs are generally polysaccharide based such as Lentinan (from shiitake mushrooms) and Polyactin A (also known as alpha-glucomannan). While these drugs are not currently used in the United States, there are a number of dietary supplements available that may have the same effect. Aloha Medicinals, Inc., has done research for several years on the use of immuno-modulators as dietary supplements for concommitant use in difficult to treat diseases such as Lyme. This was an offshoot from the tracking of results obtained from the use of their original Immune-Assist™ product, a condition specific dietary supplement intended for use by cancer patients while undergoing conventional treatment. Although originally intended as a cancer treatment enhancer, the mode of action is strictly immuno-modulatory, and led to the development of their second generation of Immunomodulatory supplements. In particular,Immune-Assist™ Daily Formula has shown effectivness for supplementing the immune system while undergoing treatment for Lyme disease as well as several other difficult to treat diseases such as hepatitis and AIDS. It seems logical that this approach may be especially useful in the hard-to-treat, later stages of CNS lyme. This is probably because the immune stimulation response it provides is not limited by the blood/brain barrier, as are conventional antibiotics. It seems that immunomodulator supplements may act as enhancements for the antibiotics usually used for Lyme treatment, increasing their effectivness.
ADDITIONAL THERAPEUTIC AND PREVENTIVE APPLICATIONS FOR IMMUNE-ASSIST™
Owing to its tremendous immune enhancing effects, Immune-Assist™ is likely to be of significant benefit to individuals suffering from a wide range of conditions.  Impaired immunity is a result of a wide range of poor lifestyle habits including high stress levels, exposure to high levels of toxins, and poor nutritional status.  As such individuals in the following categories could also benefit from Immune Assist™:
 Individuals who constantly work with paint (artists, house painters, etc)
 Chemical and refinery workers and others exposed to heavy doses of toxic chemicals
 Heavy smokers
 Heavy drinkers
 Individuals with gum disease
 Individuals with peptic ulcers
 Individuals with prostate infections
 Individuals with chronic fatigue syndrome
 Individuals with diabetes
 Individuals with heart disease
 Individuals experiencing autoimmune deficiencies (multiple sclerosis, lupus, rheumatoid arthritis)
 Individuals with recurrent infections, such as colds, flu, yeast, and parasites
 Individuals whose families exhibit a significant history of cancer
 Individuals with slow healing wounds
IMMUNE-ASSIST™ DOSAGES
The dosages used in studies are scientifically based on repeated NK cell activity tests. As such, they are consistent and easy to follow. They fall into two types:
1) For cancer, HIV or other life-threatening condition, take 3 grams per day for two-to-four weeks, then 1 gram per day until the problem is resolved.  Some people continue to take the maintenance dosage even after the problem has been resolved, while others stop taking it and resume if the problem returns.  In rare cases taking as much as 6 grams daily was necessary.
2) As a form of prevention take 1 gram per day.
In all of the studies, it has been found that taking 3 grams a day resulted in a dramatic increase in NK cell activity within one to two weeks. At the lower dosage of only 1 gram per day, the same activity wasn’t reached until about four weeks. Thus, the initial heavy doses of 3 grams per day.  Even after the dosage is dropped back to 1 gram per day, NK cell activity will continue to increase.  It is best to take the Immune-Assist™ capsules with meals in divided doses.  For example, when taking 3 grams a day (which works out to 6 500 mg capsules), 2 capsules can be taken with each meal. When you reduce the dosage down to 1 gram a day (2 capsules), you can take one capsule at breakfast and one at dinner.
REFERENCES
1) Healing Mushrooms by Dr. Georges Halpern, MD, PhD., 2007
Perhaps the most useful book currently available on Medicinal Mushrooms:
http://www.alohamedicinals.com/HealingMush_Private_10-18-06.pdf
Mushrooms have been used as medicines by humans for 5,000 years or more. As you will see, many mushrooms have properties that can improve your health and well-being. This book presents the fascinating story of eight healing mushrooms: maitake, reishi, shiitake,Cordyceps sinensis, Agaricus blazei, Phellinus linteus, Trametes versicolor, and Hericium erinaceus, as well as recent findings on additional mushrooms. It explains how ancient peoples used these mushrooms and the promise they bring for healing and preventing illness in the modern world. This book presents the latest scientific and clinical research, describes the most up-to-date experiments, and conjectures about mushrooms and their power to heal.
Contents:
Acknowledgments, v
1. An Introduction to Healing Mushrooms, 1
2. Mushrooms—East and West, 9
3. The Healing Power of Mushrooms, 19
4. Maitake, 35
5. Shiitake, 47
6. Reishi, 55
7. Cordyceps sinensis, 65
8. Agaricus blazei, 87
9. Phellinus linteus, 95
10. Trametes versicolor, 99
11. Hericium erinaceus, 107
12. Miscellaneous Mushrooms, 113
13. Mushroom Cultivation, 121
14. A Buyer’s Guide to Mushrooms, 127
Conclusion, 135
Resources, 137
Mushroom Recipes, 145
References, 157
Index, 177
2) Medicinal Mushrooms: their Therapeutic Properties and Current Medical Usage with Special Emphasis on Cancer Treatments. 2001
Authors: JOHN E SMITH BSc MSc PhD DSc FIBiol FRSE Emeritus Professor of Applied Microbiology, University of Strathclyde Chief Scientific Officer, MycoBiotech Ltd, Singapore
NEIL J ROWAN BSc MSc PhD MIBiol MIFST Lecturer, Department of Bioscience, University of Strathclyde
RICHARD SULLIVAN BSc MD PhD Head of Clinical Programmes, Cancer Research UK
Many of the currently available anti-cancer agents are derived form natural products, for instance paclitaxel (Taxol), and camptothecin (Hycamtin) amongst many others. In 2000 Professor Gordon McVie, Director-General of the Cancer Research Campaign (now Cancer Research UK) and Professor John Smith of University of Strathclyde met in Glasgow to discuss the role of medicinal mushrooms in the treatment of cancer. The CRC had become aware that these natural products were being used extensively in the Far East as nutriceuticals (dietary supplements) and as a source for the generation of pharmaceutical-grade medicines to treat a wide variety of diseases, including cancer. The substantial range of medicinal mushroom species from which different bioactive compounds can be derived suggested that the humble mushroom could be a source of novel anti-cancer agents.
This monograph is a comprehensive overview of this subject from the technology of cultivation, extraction and chemistry of medicinal mushroom bioactive compounds to the clinical evidence that suggests an important therapeutic role in cancer, and other major diseases.
The monograph is available for download on a chapter by chapter basis as PDF documents. If you don’t have a copy of Adobe Acrobat, you can download a copy from their website atwww.adobe.com/products/acrobat/readstep.html. If you are having difficulty downloading the monograph – some of the sections are quite large due to high quality images – please contact Cancer Research UK via the email or phone details listed below to obtain a CD copy.
Executive Summary (33KB)
Front page (13KB)
Preamble (16KB)
Index (9KB)
Chapter 1 – Introduction (37KB)
Chapter 2 – Nature of fungi with special emphasis on mushrooms (1,451KB)
Chapter 3 – Medicinally important mushroom
Part A (1.61MB)
Part B (1.68MB)
Part C (1.8MB)
Part D (3.1MB)
Chapter 4 – Technology of mushroom cultivation (339KB)
Chapter 5 – Extraction, development and chemistry of anti-cancer compounds from medicinal mushrooms (400KB)
Chapter 6 – Immunomodulatory activities of mushroom glucans and polysaccharide-protein complexes in animals and humans (217KB)
Chapter 7 – The role of polysaccarides derived from medicinal mushrooms in cancer (134KB)
Chapter 8 – Additional medicinal properties (85KB)
Chapter 9 – Regulatory and safety criteria for functional foods and dietary supplements and pharmaceutical medicines; the role for medicinal mushrooms (68KB)
Chapter 10 – Conclusions (50KB)
Appendix 1 (604KB)
Appendix 2 (13KB)
Appendix 3 (18KB)
Biographies (10KB)
Acknowledgements (7KB)
3) Anti-Cancer Properties: A peer-reviewed article by Dr. Solomon Wasser of University of Haifa, Israel : Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides  (PDF 269 kb)
Prepared by
Health Products Distributors, Inc.
PO Box 5600
Oracle, AZ  85623
1-800-228-4265
hpdi@mindspring.com
www.IntegratedHealth.com